Order By Item Count
Order Alphabetically

• 16 gene recurrence score (1)
• 177Lu-DOTATATE (1)
• 17p deletion (1)
• 18F-fluciclovine PET/CT (1)
• 2015 Palliative Care in Oncology (16)
• 2016 ASTRO Annual Meeting (16)
• 2016 GI Cancers Symposium (15)
• 2016 NCCN Annual Meeting (21)
• 2016 NCCN Annual Meetng (1)
• 2016 NCCN guidelines (1)
• 2016 Palliative Care in Oncology (16)
• 2016 Quality Care Symposium (17)
• 2016 Survivorship Symposium (14)
• 2017 Cancer Survivorship Symposi (1)
• 2017 Quality Care Symposium (1)
• 2017 San Antonio Breast Cancer S (1)
• 21 gene score (1)
• 21-gene recurrence score (1)
• 21st Annual NCCN Conference (1)
• 3-D conformal radiation (1)
• 4R model (1)
• 5-fluorouracil (1)
• 5FU (1)
• 5-FU (1)
• 5HT3 antagonist (1)
• 5HT3 receptor (1)
• 7+3 chemotherapy (1)
• A. Collier Smyth (1)
• A. Craig Lockhart (2)
• A. Kate Macdougall (4)
• A. Oliver Sartor (5)
• aacr 2020 (10)
• AACR Covid and Cancer (7)
• aacr virtual annual meeting (1)
• AACR Virtual II (12)
• Aakash Desai (1)
• Aaksh Desai (2)
• Aalaa Mahmoud (1)
• Aaron Martin (1)
• Aaron Sasson (1)
• AARON TALLENT (2)
• Abby B. Sandler (1)
• Abby Rosenberg (1)
• ABCSG trial (1)
• ABCSG-16 trial (1)
• ABCSG-18 (1)
• ABCSG-18 trial (1)
• abemaciclib (3)
• abiraterone (9)
• abiraterone acetate (6)
• ablation (1)
• Abramson Cancer Center (3)
• abscopal responses (1)
• ABVD chemotherapy (1)
• AC (2)
• aca (2)
• academic cancer center (1)
• academic health centers (1)
• academic hospital (1)
• acalabrutinib (1)
• acalabrutinib, asco 2019, chronic lymphocytic leukemia, cll, obinutuzumab (1)
• ACCC (5)
• accelerate treatment (1)
• accelerated fractionation radiot (1)
• access (2)
• access to care (2)
• access to opioids (1)
• ACCORD12 trial (2)
• ACCRU trial (1)
• ace-536 (1)
• activated RAS (1)
• active cancer surveillance (1)
• active surveillance (1)
• active symptom control (1)
• active treatment (1)
• ACTIVE8 trial (1)
• acts-cc 02 trial (1)
• acupuncture (2)
• acute care (1)
• acute lymphoblastic leukemia (8)
• acute lymphocytic leukemia (1)
• acute myeloblastic leukemia (1)
• acute myeloid leukemia (14)
• acute toxicity (1)
• Adam Brufsky (1)
• Adam Hayden (1)
• Adam Metwalli (1)
• Adam Stern (1)
• Adam Sutton (1)
• ADAPT trial (1)
• adc (1)
• adcs (1)
• adenocarcinoma (4)
• adipocytic sarcoma (1)
• adipokines (1)
• adjustment disorders (1)
• adjuvant (10)
• adjuvant analgesics (1)
• adjuvant chemotherapy (11)
• adjuvant docetaxel (1)
• adjuvant endocrine therapy (3)
• adjuvant endocrine treatment (1)
• adjuvant endorcine therapy (1)
• adjuvant hipec (1)
• adjuvant radiotherapy (2)
• adjuvant therapy (6)
• adjuvant treatment (3)
• adolescent cancer (1)
• adolescent cancer survivor (1)
• adolescent oncology (1)
• adolescent survivor (1)
• adolescents (1)
• Adolfo González Serrano (1)
• adoptive cell therapy (1)
• ado-trastuzumab emtansine (1)
• adriamycin (1)
• Adrienne Boissy (1)
• Adrienne R. Boissy (1)
• Adrienne Scheck (1)
• ADT (9)
• adult ALL (1)
• adult cancer (1)
• advance care planning (1)
• advance of the year (1)
• advanced bladder cancer (1)
• advanced breast cancer (7)
• advanced cancer (9)
• advanced cancer care (1)
• advanced colorectal cancer (1)
• advanced disease (3)
• advanced lung cancer (3)
• advanced lymphoma (1)
• advanced melanoma (2)
• advanced NSCLC (2)
• advanced phase leukemia (1)
• advanced practice nurse (1)
• advanced prostate cancer (1)
• advanced refractory cancer (1)
• advanced solid tumor (1)
• advanced urothelial carcinoma (1)
• advanced-stage disease (1)
• advances in therapy (1)
• adverse events (9)
• advocacy (1)
• advocate (1)
• aethera trial (1)
• afatinib (6)
• affordability (2)
• affordability of care (1)
• affordable care (1)
• Affordable Care Act (3)
• affordable drug initiative (1)
• African American (2)
• African Americans (1)
• age 40 (1)
• age 50 (1)
• agent-based therapy (2)
• aggressive lymphomas (1)
• aggressive medical care (1)
• aggressive myeloma (1)
• aggressive therapy (1)
• aggressive treatment (2)
• aging population (1)
• agnostic therapy (1)
• AHCT (3)
• AHMED ELHAJ (1)
• AI (1)
• Aichi Cancer Center Hospital (1)
• AIO trial (1)
• Aix Marseille University (2)
• Ajay Nooka (2)
• Ajeet Gajra (1)
• Aju Mathew (1)
• Akila Viswanathan (1)
• akt1 mutation (1)
• akt3 (1)
• Al Benson (3)
• Alain Ravaud (2)
• alan f. list (8)
• Alan List (2)
• Alan Pollack (1)
• Alan Venook (2)
• Albert Deisseroth (1)
• Alcala de Henares University (1)
• ALCHEMIST (1)
• ALCYONE trial (1)
• Alec Kupelian (1)
• alectinib (3)
• Aleix Prat (2)
• Alejandro Chaoul (1)
• Alejandro Salicrup (1)
• ALESIA (1)
• Alessandra Tedeschi (2)
• Alex Carney (1)
• Alex Carolan (3)
• Alex Francisco Herrera (1)
• Alex Herrera (1)
• Alex Sieg (1)
• ALEX trial (1)
• Alexander Andreev-Drakhlin (1)
• Alexander Eggermont (1)
• Alexander N. Shoushtari (1)
• Alexander Pine (1)
• Alexander R. Ende (1)
• Alexander van Akkooi (1)
• Alexandra Maertens (1)
• Alexandra Vitale (1)
• Alexis Browning (1)
• ALFA/Clara (1)
• Alfred Lee (1)
• Alfred Neugut (1)
• algorithm (1)
• Ali Raza Khaki (1)
• Alice Chung (2)
• Alice Goodman (1485)
• Alice Goodman and Caroline Helwick (3)
• Alice Mims (1)
• Alice Shaw (5)
• Alice Tsang Shaw (2)
• Aline Charabaty (1)
• Aline Fusco Fares (1)
• Alison Jefferies (1)
• Alison Loren (2)
• ALK (4)
• ALK fusion (1)
• ALK inhibitors (1)
• ALK positive (2)
• ALK testing (1)
• ALL (12)
• Allan Espinosa (1)
• Allegheny General Hospital (1)
• Allen Lichter (9)
• alliance (1)
• ALLIANCE A031201 trial (1)
• ALLIANCE A031203 trial (1)
• Alliance trial (2)
• Allison Applebaum (9)
• Allison Harvey (1)
• Allison Kurian (1)
• Allison Magnuson (1)
• Allison Rosen (1)
• allogeneic hematopoietic cell tr (4)
• allogeneic stem cell transplanta (2)
• Alok Khorana (2)
• alopecia (2)
• alpelisib (1)
• ALSYMPCA trial (1)
• ALTERNATE trial (1)
• Aly-Khan Lalani (1)
• Alysa Fairchild (2)
• Aman Buzdar (1)
• Amanda Blair (1)
• Amanda J. Redig (1)
• Amanda McIntyre (1)
• Amanda Narod (3)
• ambulatory (1)
• Amelie Harle (2)
• Amer Zeidan (1)
• American cancer disparities (1)
• American Cancer Society (7)
• American Indian (1)
• American Indians (1)
• American Medical Association (1)
• American Society for Radiation O (1)
• american society of hematology (31)
• american society of hematoly (1)
• American University of Beirut (1)
• Ami Chitalia (1)
• Amina Ahmed (1)
• Aminah Jatoi (1)
• Amir Steinberg (1)
• Amit Kulkarni (1)
• Amit Mahipal (1)
• Amitabh Gulati (1)
• AML (18)
• Amy Cyr (2)
• Amy Kiamos (1)
• Amy MacKenzie (3)
• Amye Tevaarwerk (1)
• Ana I. Tergas (1)
• Ana Maria López (1)
• Anahid Hamparsumian (1)
• anal squamous cell cancer (1)
• anamorelin (3)
• anaplastic (1)
• anaplastic glioma (1)
• anaplastic oligodendroglioma (1)
• Anas Younes (3)
• anastrozole (11)
• and L. Jeffrey Medeiros (1)
• andecaliximab (1)
• Anders Widmark (1)
• Andrea Ferrari (1)
• Andrea Lim (1)
• Andrea Patenaude (1)
• Andrea Watson (2)
• Andreas Engert (3)
• Andreas Hochhaus (1)
• Andreas Rimner (1)
• Andrew Armstrong (6)
• Andrew Chapman (1)
• Andrew Chi (1)
• Andrew Clamp (1)
• Andrew Davies (2)
• Andrew Dunbar (1)
• Andrew Evens (2)
• ANDREW HAHN (1)
• ANDREW HERTLER (1)
• Andrew James Martin (3)
• Andrew Ko (2)
• Andrew Martin (1)
• Andrew Roth (2)
• Andrew S. Epstein (1)
• Andrew Seidman (24)
• Andrew Zelenetz (10)
• Andriy Hrynkiv (1)
• androgen deprivation (3)
• androgen deprivation therapy (6)
• androgen receptor (1)
• androgen receptor-positive (1)
• androgen suppression (1)
• androgen-deprivation therapy (7)
• androgens (1)
• Andy Lindsay (1)
• Anees Chagpar (2)
• anemia (2)
• anesthetics (1)
• Angela Bradbury (1)
• Angela Pang (1)
• angiosarcoma (1)
• Anil D'Cruz (2)
• Anil Sood (1)
• Animesh Pardanani (1)
• Anis Hamid (1)
• Anita D'Souza (2)
• Anita Mahajan (2)
• Anita O'Donovan (1)
• Anjali Advani (1)
• Ann Farrell (1)
• Ann Graham (1)
• ann h. partridge (1)
• Ann Klopp (1)
• Ann Partridge (8)
• Ann Ramer (1)
• Anna Patrikidou (1)
• Anna Rachelle Mislang (1)
• Anne Blaes (2)
• Anne Chiang (1)
• Anne Covey (1)
• Anne Jacobs (1)
• Anne Katz (1)
• Anne Kimha (1)
• Annick Desjardins (1)
• Annie Howell (1)
• Ann-Lii Cheng (1)
• announce trial (1)
• anorexia (3)
• Anschutz Cancer Pavilion (1)
• Anthony Back (3)
• ANTHONY D’AMICO (1)
• Anthony D'Amico (3)
• Anthony Olszanski (11)
• Anthony Perre (1)
• Anthony Zietman (6)
• anthracycline (3)
• anthracycline-based chemotherapy (1)
• antiandrogen therapy (2)
• anti-androgen therapy (1)
• antiangiogenic (1)
• antiangiogenic agent (1)
• anti-B-cell maturation antigen (1)
• antibiotics (1)
• antibody blockade (1)
• antibody drug conjugate (1)
• antibody IMAB362 (2)
• antibody-drug conjugate (2)
• anti-CD19 (2)
• anti-CD19 monoclonal antibody (1)
• anti-CD22 (1)
• anticoagulation (1)
• anticonvulsant (1)
• anti–CTLA-4 (1)
• antidepressant agents (1)
• antiestrogen therapy (1)
• anti-GD2 (2)
• anti-PD-1 (1)
• anti–PD-1 (3)
• anti–PD-L1 (1)
• anti-PD-L1 antibody (1)
• anti-PLD1 monoclonal antibody (1)
• antipsychotic (1)
• antitumor effect (1)
• antitumor immunity (1)
• anti-VEGF (1)
• Anton Barchuk (1)
• Antonio C. Wolff (1)
• Antonio Castaneda (2)
• Antonio Palumbo (2)
• anxiety (6)
• ANZUP (3)
• apact (1)
• apalutamide (2)
• Apar Kishor Ganti (4)
• apatorsen (1)
• APHINITY trial (1)
• APL (1)
• app (2)
• aprepitant (3)
• Aram Demirjian (1)
• aramis trial (2)
• Arash Asher (1)
• ARCHER 1050 (1)
• ARCHER 1050 trial (1)
• Areej El-Jawahri (3)
• ARIEL3 (1)
• Arielle Elkrief (2)
• Arizona Breast Cancer Specialist (1)
• Arjun Balar (1)
• Arjun Patel (1)
• Arjun Vasant Balar (1)
• arm mobility (1)
• Armando Armas (1)
• Armando E. Giuliano (2)
• Armando Giuliano (1)
• Armando Sardi (1)
• Armitage (1)
• Arnaud Scherpereel (2)
• aromatase inhibitor (12)
• aromatase inhibitors (4)
• arrow trial (1)
• arsenic (1)
• Artemis Health Institute (1)
• Artemis Hospitals (1)
• arterial-directed therapy (1)
• arthralgia (1)
• Arti Hurria (3)
• artificial intelligence (1)
• Asan Medical Center (1)
• ASCEND-5 trial (1)
• ascend-7 (1)
• ASCENDE-RT (1)
• ASCO (1358)
• ASCO 2015 (53)
• ASCO 2016 (63)
• ASCO 2017 (55)
• ASCO 2018 (67)
• asco 2019 (69)
• asco 2019, breast cancer, capecitabine, her2-positive, lapatinib, metastatic, nala trial, neratinib (1)
• ASCO Choosing Wisely (1)
• ASCO Communications (3)
• ASCO Connection (1)
• ASCO Palliative Care (12)
• asco post (51)
• ASCO President (2)
• ASCO Publishing (1)
• ASCO Quality Care (11)
• ASCO Quality Care 2017 (13)
• asco quality training program (1)
• asco sitc (19)
• ASCO Virtual Scientific Program (1)
• ASCO20 (49)
• ASCO-ECCO (1)
• ascoo 2019 (1)
• ASCO-SITC 2017 (11)
• ASCT (3)
• ASH (5)
• ASH 2015 (33)
• ASH 2016 (25)
• ASH 2017 (11)
• ASH 2018 (18)
• ash 2020 (1)
• ash annual meeting (48)
• Asher Chanan-Khan (3)
• Ashfaq Marghoob (1)
• Ashley Cimino-Mathews (1)
• Ashley Wysong (1)
• Asian (1)
• aspire trial (1)
• aspirin (2)
• assays (1)
• Assistance Publique Hopitaux De (1)
• assisted suicide (1)
• Association of Community Cancer (1)
• ASTRO (2)
• ASTRO 2015 (19)
• ASTRO 2017 (12)
• ASTRO 2018 (11)
• astro 2020 (9)
• astro annual meeting (14)
• atempt trial (1)
• atezolizumab (24)
• Athalia Rachel Pyzer (1)
• Atiqur Rahman (1)
• atra (1)
• AUA (1)
• AUGMENT trial (1)
• AUGUSTO LEÓN (1)
• Aurelius Omlin (1)
• autoimmune disease (2)
• autologous hematopoietic cell tr (1)
• autologous stem cell transplant (6)
• autologous transplantation (1)
• autonomic imbalance (1)
• avasopasem manganese (1)
• avelumab (5)
• Avni Desai (1)
• Avraham Eisbruch (1)
• Avrum Bluming (2)
• Axel Grothey (9)
• axicabtagene ciloleucel (2)
• axillary lymph node dissection (1)
• axitinib (6)
• AYA cancer (2)
• AYA oncology (3)
• AYA survivors (1)
• ayalew tefferi (6)
• Ayesha Munir (1)
• azacitidine (6)
• AZD5363 (1)
• Azienda Ospedaliera Niguarda Cà (1)
• B.J. Rimel (1)
• B-40 trial (1)
• B-51 trial (1)
• Babara Gitlitz (1)
• baf-type (1)
• Bahar Javdan (1)
• Bain Capital Life Sciences (1)
• BALKEES ABDERRAHMAN (1)
• b-all (1)
• Barb Young (1)
• Barbara Boughton (3)
• Barbara Gitlitz (1)
• Barbara K. Rimer (1)
• Barbara McAneny (2)
• Barnardo Rapoport (1)
• Barnett Kramer (2)
• Barrie Cassileth (21)
• Barrie R. Cassileth (1)
• barriers to care (1)
• barriers to quality (1)
• Barry Paul (1)
• Barts Cancer Institute (2)
• Barts Health NHS Trust (2)
• basal cell carcinoma (2)
• basal type breast cancer (1)
• basic science (1)
• basket trial (1)
• basket trials (1)
• Bates Moses (1)
• Baylor College of Medicine (5)
• BC2001 trial (1)
• B-cell ALL (3)
• B-cell lymphoma (2)
• B-cell malignancies (1)
• B-cell non-Hodgkin lymphoma (1)
• B-cell precursor (1)
• BCG (1)
• BCIRG-006 study (1)
• bcl-2 (1)
• bcl2 inhibitor (1)
• BCMA (1)
• BEACON CRC (2)
• Beat Thürlimann (1)
• Beatriz Korc-Grodzicki (1)
• BELIEF trial (1)
• BELLE-3 trial (1)
• Bellinda King-Kallimanis (1)
• bendamustine (9)
• bendustamine (1)
• Benjamin Anderson (1)
• Benjamin Besse (2)
• Benjamin Movsas (1)
• Benjamin Smith (4)
• Benyam Muluneh (1)
• benzodiazepines (1)
• Bernard Escudier (7)
• Bernard Fisher (2)
• Bernardo Rapoport (1)
• Bertrand Coiffier (6)
• Bertrand Routy (1)
• best care (1)
• Best of ASCO (1)
• beta-thalassemia (1)
• Beth Faiman (1)
• Beth Fairchild (1)
• Beth Howard (3)
• Beth Israel Deaconess (1)
• Beth McLellan (1)
• BETTY DICKER (1)
• Betty Ferrell (2)
• Betty Hamilton (1)
• bevacizumab (29)
• Beverly Canin (1)
• Beverly Vuckovich (1)
• BGB-290 (1)
• BGB-A317 (1)
• BGJ398 (1)
• Bhavana Konda (1)
• Bhishamjit Chera (1)
• Bhuvanesh Singh (1)
• bicalutamide (4)
• big data (3)
• bilateral (1)
• bilateral mastectomy (1)
• BILCAP trial (1)
• bile duct cancer (1)
• biliary cancer (1)
• biliary tract cancer (6)
• Bill Brummel (1)
• Bill Gradishar (1)
• Bill McClain (1)
• Bin McLaurin (1)
• binimetinib (2)
• biochemical control (1)
• biochemical failure (1)
• biochemical recurrence (1)
• biochemical relapse (1)
• biologics (1)
• biology in younger patients (1)
• biology of pain (1)
• biomarker (13)
• biomarker stratification (2)
• biomarkers (10)
• biopsy (2)
• biosimilar (1)
• biosimilars (4)
• Biosimilars (1)
• biphosphonate treatment (1)
• BIRCH trial (1)
• biscay trial (1)
• Bishal Gyawali (1)
• Bishoy Faltas (5)
• bisphophonates (1)
• BITE (1)
• black patients (2)
• bladder cancer (40)
• Bladder Cancer (20)
• bladder preservation (1)
• Blase N. Polite (1)
• Blase Polite (1)
• blast phase (1)
• bleomycin (1)
• blinatumomab (4)
• blinatumumab (1)
• blood biomarker (1)
• blood cancer (1)
• blood-brain barrier (2)
• blu-667 (1)
• Bob Carlson (2)
• Bob Levis (1)
• Bobby Daly (1)
• body composition (2)
• body image (1)
• BOLERO-2 (1)
• BOLERO-4 (1)
• bone fractures (1)
• bone marrow transplant (1)
• bone metastases (3)
• Bonnie Addario (1)
• Bonnie Glisson (1)
• Bonnie Rochman (1)
• Bordeaux University Hospital (2)
• borderline disease (1)
• borderline resectable (1)
• borderline resectable pancreatic (1)
• Borealis-2 (1)
• Boris Sepesi (1)
• bortezomib (7)
• bowel function (1)
• brachytherapy (3)
• brachytherapy implant (1)
• Brad Kahl (3)
• Bradley Monk (2)
• Bradley Reames (1)
• Bradley Zebrack (2)
• BRAF (2)
• BRAF mutation (2)
• BRAF mutations (1)
• BRAF V600 (2)
• braf v600e (2)
• BRAF-mutated tumors (1)
• brain cancer (5)
• brain metastases (11)
• Branden May (1)
• Brandon May (21)
• Brandon Smaglo (1)
• BRCA (8)
• BRCA mutations (1)
• BRCA status (1)
• BRCA1 (4)
• brca1/2 (1)
• BRCA2 (4)
• BRCA-mutated (1)
• breast (1)
• breast cancer (209)
• Breast Cancer (53)
• breast cancer diversity (1)
• breast cancer genomics (1)
• breast cancer in young women (2)
• breast cancer incidence (1)
• breast cancer mortality (1)
• breast cancer prevention (1)
• breast cancer screening (1)
• breast cancer survivor (3)
• breast cancer survivors (3)
• breast conservation (1)
• breast conserving surgery (2)
• breast irradiation (1)
• breast preserving surgery (1)
• breast resection (1)
• breast tumors (1)
• breast-conserving surgery (1)
• breast-conserving therapy (1)
• Brenda Sandmaier (1)
• Brendan F. Curley (1)
• Brendan Guercio (2)
• brentuximab vedotin (5)
• bretrand coiffier (1)
• Brett Wilson (1)
• Bria Meyer (2)
• Brian Bolwell (1)
• Brian Chapin (1)
• Brian Chen (1)
• Brian Kavanagh (2)
• Brian Rini (5)
• Brian Weiss (1)
• Brian Wolpin (1)
• Bridgett Harr (2)
• brigatinib (1)
• Brigham and Women’s (1)
• Brigham and Women’s Hospital (1)
• Brigham and Women's Cancer Center (1)
• Brigham and Women's Hospital (1)
• BRIM8 trial (1)
• Brinker Award lecture (1)
• British Columbia Cancer Agency (4)
• Britta Weigelt (1)
• Brittany Bychkovsky (1)
• brocade 3 (1)
• bronchoscopy (1)
• Bruce A. Chabner (1)
• Bruce Cheson (6)
• Bruce E. Johnson (1)
• Bruce Haffty (1)
• Bruce Johnson (3)
• Bruce Levine (2)
• Bruce Minsky (5)
• Bruno Medeiros (1)
• Brustzentrum der Universität Mün (1)
• bruton's tyrosine kinase (1)
• BTK (2)
• BTK inhibitors (2)
• buparlisib (1)
• burden (1)
• burden of care (1)
• burden of treatment (1)
• Burkitt lymphoma (2)
• Burkitt’s lymphoma (1)
• bursectomy (1)
• business (5)
• C.B. Allard (1)
• cabazitaxel (4)
• CABOSUN (1)
• CABOSUN trial (1)
• cabozantinib (9)
• cachexia (5)
• cachexia quality of life (1)
• CAF (1)
• calcium (1)
• Caleb Dulaney (1)
• CALGB 40502 (1)
• CALGB 40503 (1)
• CALGB 40601 (1)
• CALGB 40601 Alliance (1)
• calgb 40603 (1)
• CALGB 40903 (1)
• CALGB 80802 (1)
• CALGB 80803 (1)
• CALGB 89803 (2)
• CALGB alliance trial (2)
• CALGB trial (1)
• CALGB/Alliance 50303 (1)
• CALGB/Alliance 50604 (1)
• CALM psychological intervention (1)
• Calvin Dykstra (1)
• Cameron Turtle (2)
• cancer (60)
• Cancer and Aging Research Group (1)
• cancer biomarker (1)
• cancer care (3)
• cancer caregiving (1)
• cancer centers (2)
• Cancer Council Queensland (1)
• cancer delirium (1)
• cancer diagnosis (1)
• cancer discoveries (1)
• cancer drug development (1)
• cancer experience (1)
• cancer genetics (1)
• Cancer Genome Atlas (1)
• cancer imaging (1)
• cancer in India (1)
• cancer in South America (1)
• cancer in the Middle East (1)
• cancer incidence (2)
• cancer management (2)
• cancer metastases (1)
• cancer mortality (3)
• cancer of the unknown primary (1)
• cancer outcomes (3)
• cancer pain (8)
• cancer pain management (1)
• cancer prevention (2)
• cancer recurrence (4)
• cancer research (4)
• Cancer Research UK (1)
• Cancer Research UK Centre (1)
• cancer risk (1)
• cancer screening (6)
• cancer staging (4)
• cancer support services (1)
• cancer surgery (1)
• cancer survival (1)
• cancer survivor (16)
• cancer survivors (1)
• cancer survivorship (4)
• Cancer Survivorship Symposium (23)
• cancer treatment (6)
• Cancer Treatment Centers of Amer (2)
• cancer treatment outcomes (1)
• cancer vaccine (2)
• cancer vaccines (1)
• CancerCare (1)
• CancerLinQ (4)
• cancer-related pain (1)
• cancer-specific survival (1)
• candor trial (1)
• capecitabine (15)
• caplacizumab (1)
• CAPTIVATE trial (1)
• car t (1)
• CAR T cell (1)
• CAR T cell therapy (2)
• CAR T cells (2)
• CAR T-cell (3)
• car t-cell therapy (6)
• CAR T-cells (2)
• CAR therapy (1)
• Cara Glynn (1)
• Carbone Cancer Center (2)
• carboplatin (12)
• carcinomatosis (1)
• CARD trial (1)
• cardiac effects (1)
• cardiac radiation (1)
• cardiac toxicity (1)
• Cardiff University (1)
• Cardinale Smith (1)
• cardiotoxicity (2)
• cardiovascular (1)
• cardiovascular disease (3)
• cardiovascular toxicities (1)
• care coordination (1)
• care disparities (1)
• care plan (2)
• care program (1)
• caregiver (2)
• caregivers (2)
• Carey Anders (2)
• carfilzomib (5)
• Carina Storrs (1)
• Carl Singerman (1)
• CARLA CASULO (1)
• Carlo Alfredo Clerici (1)
• Carlos Arteaga (2)
• Carlos Barrios (1)
• Carlos Rene Valdez (1)
• Carmea trial (2)
• carmena (1)
• Carol Goodrich (1)
• Carol Kuehnert (1)
• Carol Lee (1)
• Carol Tietz (1)
• Carol Veio (1)
• CAROLINA TANNENBAUM-BARUCHI (1)
• Carolina Urologic Research Center (1)
• Carolinas Medical Center (1)
• Caroline Helwick (2061)
• Caroline Helwick and Alice Goodman (3)
• Caroline Hopkins (3)
• Caroline McNeil (69)
• Caroline Robert (2)
• Caroline Wellbery (1)
• Carolyn Hendricks (1)
• Carolyn Matthews (1)
• Carolyn Presley (2)
• Carolyn Runowicz (1)
• Carrie Kreiswirth (1)
• Carrie Snyder (1)
• Carson Rolleri (4)
• CAR-T (2)
• CAR-T cells (1)
• cas9 (1)
• CASSINI (1)
• castelman disease (1)
• castleman disease collaborative network (1)
• CASTOR trial (4)
• castrate-resistant (2)
• castration resistant (1)
• castration-resistant (14)
• castration-resistant prostate ca (2)
• castration-sensitive (3)
• Catherine C. Coombs (1)
• Catherine Coombs and Anthony Mato (1)
• Catherine Park (2)
• Catherine Thieblemont (2)
• Cathy Eng (2)
• CATNON trial (1)
• Catriona McNeil (3)
• catumaxomab (1)
• Caucasian (1)
• cause-specific mortality (1)
• CBT (1)
• cc-486 (1)
• CCF (2)
• CCGA (1)
• CCOG 1102 (1)
• CCTG/AGITG napabucasin (1)
• CD19 (1)
• CD-19 (1)
• CD19+ lymphoma (1)
• CD-20 positive (1)
• CD274 (1)
• CD30 (2)
• CD-30 (1)
• CD38 (1)
• cd79a (1)
• CD81 cells (1)
• CDK inhibitor (1)
• CDK4 inhibitor (1)
• CDK4/6 inhibitor (1)
• CDK4/6 Inhibitors (1)
• CDK46 (1)
• CEA tumor marker (1)
• Cedars-Sinai (6)
• Cedars-Sinai Medical Center (3)
• cediranib (1)
• Ceilidh Eaton Russell (1)
• celecoxib (1)
• Celestia Higano (2)
• CELESTIAL (2)
• cell-free DNA (1)
• cellular therapy (2)
• cemiplimab (2)
• Center for International Blood a (1)
• central nervous system metastase (1)
• Centre Antoine-Lacassagne (2)
• Centre Eugene Marquis (2)
• Centre Leon Berard (1)
• Centre Léon Bérard (1)
• Centre R Gauducheau (1)
• Centre Régional de Lutte Contre (1)
• CEO (1)
• Cerdulatinib (1)
• ceritinib (4)
• cervical cancer (8)
• Cesar A. Santa-Maria (2)
• Cesar Santa-Maria (1)
• cetuximab (10)
• ch14.18/CHO (2)
• CHAARTED trial (1)
• Chadi Nabhan (1)
• challenges in cancer care (1)
• Chanan-Khan (1)
• Chandrakanth Are (43)
• Channing Paller (5)
• Charity Oyedeji (1)
• Charles Bennett (4)
• Charles Blanke (1)
• Charles Drake (1)
• Charles Duvall (2)
• charles e. geyer (2)
• Charles E. Geyer Jr. (3)
• Charles F. von Gunten (2)
• Charles L. Bennett (5)
• Charles Loprinzi (2)
• Charles Rudin (1)
• CHARLES RYAN (1)
• Charles Schiffer (2)
• Charles Simone (1)
• Charles von Gunten (3)
• charlo (1)
• Charlotte Bath (701)
• CHARU AGGARWAL (2)
• Chase Doyle (510)
• chasing my cure (1)
• Chau Dang (2)
• Checkmate (2)
• CheckMate 025 (1)
• CheckMate 032 (3)
• CheckMate 039 (1)
• CheckMate 067 (1)
• CheckMate 141 (1)
• CheckMate 142 (1)
• CheckMate 214 (2)
• CheckMate 214 trial (1)
• checkmate 227 (1)
• checkmate 238 (1)
• CheckMate 238 trial (1)
• CheckMate 275 (1)
• checkmate 384 (1)
• checkmate 650 (1)
• CheckMate 67 (2)
• CheckMate-032 (1)
• CheckMate-142 (2)
• checkpoint antibodies (2)
• checkpoint blockade (3)
• checkpoint inhibitor (4)
• checkpoint inhibitors (5)
• checkpoint kinase inhibitor (1)
• chemobrain (1)
• chemoendocrine (2)
• chemoimmunotherapy (4)
• chemoimmunotherapy, first-line therapy, follicular lymphoma, nccn hematologic malignancies, targeted biologics (1)
• chemopreventative (2)
• chemoradiation (6)
• chemoradiotherapy (9)
• chemoresistance (1)
• chemotherapy (80)
• chemotherapy duration (1)
• chemotherapy errors (1)
• chemotherapy naive (1)
• chemotherapy toxicity (1)
• chemotherapy-induced (1)
• chemotherapy-induced peripheral (1)
• chemotherapy-ineligible (1)
• chemotherapy-naive (3)
• chemotherapy-naïve (1)
• Cheryl Ewing (1)
• Cheryl Krafft (1)
• chest infections (1)
• chest wall radiation (1)
• Chevalier Jackson (1)
• CHHiP trial (2)
• Chiara Magni (1)
• Chijioke Nze (1)
• childhood ALL (2)
• childhood cancer (2)
• childhood cancer survivor (2)
• Childhood Cancer Survivor Study (1)
• childhood cancer survivors (2)
• children (1)
• Children’s Oncology Group (1)
• chimeric antigen receptor (5)
• China (1)
• Chinese U of Hong Kong (1)
• Chinese University (1)
• Chinese University of Hong Kong (5)
• Chip Baldwin (1)
• Chloe Atreya (2)
• chlorambucil (2)
• cholangiocarcinoma (2)
• Choosing Wisely Campaign (1)
• CHOP (2)
• CHOP-R (1)
• CHP (1)
• CHRIS LABAKI (1)
• Chris Leonardis (1)
• Chris O'Brien Lifehouse (1)
• Chris Parker (1)
• Christian Blank (2)
• Christian Carrie (2)
• Christian Nelson (1)
• Christian-Albrechts University K (2)
• Christiane Querfeld (1)
• Christiane Voit (1)
• Christie NHS Foundation Trust (3)
• Christina Best (1)
• Christina Chu (2)
• Christina S. Chu (1)
• Christina Seluzicki (1)
• Christine Berg (1)
• Christine Boers-Doets (1)
• Christoph Zielinski (2)
• Christopher Allard (1)
• Christopher Barker (1)
• Christopher Buettner (1)
• Christopher Campen (5)
• Christopher Flowers (1)
• CHRISTOPHER HOIMES (1)
• Christopher Kelsey (1)
• Christopher Logothetis (1)
• Christopher Recklitis (4)
• Christopher Rose (2)
• Christopher Steer (1)
• Christopher Sweeney (9)
• Christopher Willett (1)
• chronic disease (1)
• chronic lymphocytic leukemia (21)
• chronic morbidity (1)
• chronic myeloid leukemia (8)
• chronic myelomonocytic leukemia (1)
• chronic pain (1)
• chronic-phase CML (2)
• Chung-Han Lee (1)
• Ciara Freeman (1)
• CIBMTR (1)
• CIBOMA/GEICAM Trial (1)
• Cicely Saunders (1)
• Cincinnati Children's Hospital M (1)
• Cindy Brown (1)
• Cindy Chavez (1)
• CINV (3)
• CINV prevention (1)
• CIPN (1)
• circulating free DNA (2)
• circulating tumor cells (6)
• circulating tumor DNA (10)
• cisplarin (1)
• cisplatin (19)
• cisplatin-based chemotherapy (2)
• cisplatin-ineligible (2)
• Città della Salute e della Scie (1)
• City of Hope (19)
• Clara Bloomfield (1)
• claridhy trial (1)
• classical Hodgkin lymphoma (1)
• Claus Garbe (4)
• Clayton B. Hess (1)
• CLDN18.2 positive disease (2)
• clear cell (2)
• clear cell rcc (1)
• clear cell renal cancer (1)
• CLEOPATRA trial (1)
• Cleveland Clinic (19)
• Cliff Goodman (1)
• Cliff Hudis (5)
• clifford a. hudis (2)
• Clifford Goodman (1)
• Clifford Hudis (31)
• clinical (1)
• clinical benefit (1)
• clinical cancer advances (1)
• clinical decision-making (2)
• clinical endpoint (1)
• clinical management (1)
• clinical outcomes (2)
• clinical pathways (2)
• clinical practice (1)
• clinical research (1)
• clinical resources (1)
• clinical treatment score (1)
• clinical trial (1)
• clinical trial eligibility (2)
• clinical trial screening (1)
• clinical trials (12)
• clinician-patient communication (1)
• CLL (29)
• clofarabine (1)
• CME (1)
• CML (10)
• CMML (2)
• CMS (2)
• CNS cancer (1)
• CNS cancers (1)
• CNS Cancers (1)
• CNS disease (1)
• CNS involvement (1)
• CNS metastases (1)
• CNS prophylaxis (2)
• CNS-penetrable (1)
• cobimetinib (1)
• cognition (1)
• cognitive behavior therapy (1)
• cognitive decline (1)
• cognitive failure (1)
• cognitive function (3)
• Coiffier (1)
• co-insurance (1)
• Cold Spring Harbor Laboratory (1)
• Colette Owens (1)
• Colin Weekes (1)
• colitis (2)
• collaborative pain management (1)
• collection kit (1)
• COLLEEN M. FELTMATE (1)
• Colleen Smith (1)
• COLO-001 trial (1)
• colon cancer (11)
• colony-stimulating factors (1)
• colopec trial (1)
• colorectal (1)
• colorectal cancer (36)
• Colorectal Cancer (24)
• colorectal cancer liver metastases (1)
• colorectal cancer survivor (1)
• Columbia University (2)
• Columbia University Medical Cent (2)
• Columbia University Medical Center (1)
• COLUMBUS trial (1)
• COMBI-AD (1)
• combination immunotherapy (4)
• combination therapies (3)
• combination therapy (3)
• combination treatments (1)
• combined positive score (1)
• Coming Soon (1)
• Commission on Cancer (1)
• communication barrier (1)
• communication in oncology (2)
• communication studies (1)
• community (1)
• community cancer center (1)
• community oncology (7)
• community practice (2)
• community practices (1)
• community setting (2)
• community sites (1)
• comorbidites (1)
• comorbidities (3)
• comorbidity score (1)
• comorbitides (1)
• compass trial (2)
• completely resected (1)
• complication rate (1)
• comprehensive cancer centers (1)
• computed tomography (1)
• computer assistance (1)
• computerized evaluation (1)
• concurrent radiation (1)
• Cone Health Cancer Center (1)
• conformal radiation (1)
• Conquer Cancer Foundation (2)
• Conquer Fear (1)
• consolidation chemotherapy (1)
• consolidation radiotherapy (1)
• consolidative radiotherapy (1)
• consolidative therapy (1)
• continued care (1)
• continuing medical education (1)
• contralateral breast cancer (1)
• conventional (1)
• conventional fractionation radio (1)
• conventionally fractionated (2)
• conventionally fractionated radi (1)
• conversation guides (1)
• co-occurring mutations (1)
• cooling cap (1)
• COPD (1)
• Copenhagen University Hospital (4)
• coping mechanisms (1)
• Cora N. Sternberg (1)
• Cora Sternberg (6)
• CORAL trial (1)
• core biopsy (1)
• Corey Cutler (1)
• Cornelis van de Velde (1)
• coronary calcification (1)
• coronary heart disease (1)
• coronavirus (34)
• coronavirus italy (4)
• coronavirus waves (1)
• correlative studies (1)
• cosmesis (1)
• cosmetic outcome (1)
• cost (1)
• cost analysis (2)
• cost benefit (1)
• cost curve (1)
• cost of care (21)
• Cost of Care (2)
• cost reductions (1)
• cost savings (1)
• cost-effectiveness (3)
• cough (2)
• cough mechanisms (1)
• counseling (1)
• course of therapy (1)
• course of treatment (1)
• Courtney Davis (1)
• COVID-19 (22)
• COVID-19 (21)
• covid-19 research (1)
• COX-2 over expression (1)
• cps (1)
• CPX-351 (1)
• CR30 (1)
• Craig Alguire (1)
• Craig Earle (1)
• Craig Moskowitz (3)
• Craig Pollack (2)
• cranial radiotherapy (1)
• CREATE-X clinical trial (1)
• Creighton University (1)
• CRISPR (1)
• Cristina Meazza (1)
• criteria expansion (1)
• CRITICS trial (1)
• crizotinib (9)
• Cross Cancer Institute (1)
• crpc (3)
• Crystal Denlinger (2)
• CSF (1)
• CT follow-up (1)
• CT scan (5)
• CT screening (1)
• CT019 (1)
• cT3 rectal cancer (1)
• cT4 rectal cancer (1)
• CTCL (1)
• CTCs (5)
• ctDNA (7)
• ctla-4 (1)
• ctnda (1)
• cts5 (1)
• cultural barriers (1)
• cultural differences (1)
• CUMC (2)
• curable cancer (1)
• curative surgery (1)
• cutaneous melanoma (1)
• cutaneous SCC (1)
• cutaneous squamous cell carcinom (2)
• cutaneous T cell lymphoma (1)
• cutoff (1)
• cutting-edge treatment (2)
• CXCR4 inhibitor (1)
• cyclophosphamide (7)
• cyclosporine (1)
• Cynthia Hayes (1)
• Cynthia Sears (1)
• cystectomy (2)
• cytarabine (2)
• cytopenias (1)
• D. Ross Camidge (1)
• D538G mutation (1)
• dabrafenib (6)
• dabrafenib monotherapy (1)
• dacarbazine (2)
• dacomitinib (2)
• DA-EPOCH-R (2)
• DA-EPOCH-R trial (1)
• Dale Maloney (1)
• dalteparin (1)
• Damien Hansra (3)
• Dan Labriola (1)
• Dan Longo (2)
• Dan Shapiro (1)
• Dan Zandberg (1)
• Dana Barnea (2)
• Dana Farber (3)
• Dana Farber Cancer Insitute (3)
• Dana Farber Cancer Institute (1)
• Dana Stewart (1)
• Dana-Farber (27)
• Dana-Farber Cancer Institute (61)
• Dana-Farber Clinical Pathways (1)
• Dana-Farber Institute (1)
• Danelle James (1)
• Daniel A. Goldstein (1)
• DANIEL ANAYA (1)
• Daniel Barocas (1)
• Daniel Cahill (2)
• Daniel Chang (1)
• Daniel DeAngelo (1)
• Daniel den Hoed Cancer Center (1)
• Daniel Epner (4)
• Daniel F. Hayes (6)
• Daniel Garza (1)
• Daniel Geynisman (1)
• Daniel Goldstein (1)
• Daniel Gomez (1)
• Daniel Haller (3)
• Daniel Hamstra (1)
• Daniel Hayes (4)
• Daniel Heng (1)
• Daniel J. Lenihan (1)
• Daniel Kopans (2)
• Daniel Lin (1)
• Daniel Morgensztern (1)
• Daniel Petrylak (1)
• Daniel Rayson (4)
• Daniel Richardson (1)
• Daniel Spratt (1)
• Daniel Vilarim Araujo (1)
• Daniel Vorobiof (4)
• Daniel W. Lin (1)
• Danielle Ripley Burgess (1)
• DANIELLE THOLEY (1)
• danorubicin (1)
• daratumumab (14)
• Darcy Lewis (1)
• Dario Altieri (1)
• Dario Trapani (1)
• darolutamide (2)
• Darrell Skaggs (1)
• Dartmouth-Hitchock (1)
• dasatinib (1)
• Dasha Shkurpela (1)
• data set (1)
• DATA trial (1)
• daunorubicin (2)
• DAVID BRAUN (1)
• David Dearnaley (2)
• David Ettinger (2)
• David Fredricks (1)
• David G. Pfister (1)
• David Geffen School of Medicine (1)
• David Gerber (2)
• David Gershenson (1)
• David Gustafson (1)
• David Henry (5)
• David Hyman (1)
• David Hysong (1)
• David Ilson (3)
• David Irwin (1)
• David J. Kopsky (1)
• David Kim (1)
• David Kissane (3)
• David Korones (1)
• David M. O'Malley (1)
• David Maloney (2)
• David McDermott (1)
• David Mitchell (1)
• David Nathan (1)
• David Neises (1)
• David O’Malley (1)
• David Porter (3)
• David Posner (1)
• David Quinn (1)
• David Ryan (1)
• David Steensma (3)
• David Straus (2)
• David Tuveson (1)
• David Victorson (1)
• David Wellenstein (1)
• David Williams (1)
• David Wise (1)
• David Ziegler (1)
• Dawn Hershman (4)
• Dawn Lemanne (2)
• Dawn Yates (1)
• DBCG778 (1)
• DCIS (6)
• Dean Bajorin (3)
• Deanna King (1)
• death (1)
• Death With Dignity Act (1)
• death with dignity laws (1)
• Debbie Davis (1)
• Debbie Wasserman Schultz (1)
• debilitating grief (1)
• Deborah Doroshow (1)
• Deborah Marshall (1)
• Debra Bowler (1)
• Debu Tripathy (1)
• debulking surgery (2)
• Decipher prostate cancer classif (1)
• decision making (1)
• decision support (1)
• decision-making (1)
• decitabine (1)
• DECOG trial (2)
• Dee Sparacio (1)
• deep molecular response (1)
• deep remission (1)
• Deepa Wadhwa (1)
• de-escalating therapy (1)
• Defense Health Agency (1)
• deintensification (1)
• deintensified therapy (1)
• delay in care (1)
• delirium (1)
• delivery of care (1)
• denintuzumab mafodotin (1)
• Denise Lee (1)
• Denise Leprine (1)
• DENISE MILLSTINE (1)
• Denise Yardley (1)
• denosumab (3)
• depression (9)
• Derek Jonker (1)
• Derek Raghavan (15)
• dermatologic toxicities (1)
• Derriford Hospital (1)
• despair (1)
• DESTINY study (1)
• developing world (1)
• Devorah Aschendorf (1)
• dexamethasone (14)
• dfs (1)
• diagnosis (2)
• diagnostic criteria (1)
• diagnostics (2)
• Diana Byrnes (1)
• Diana Eccles (1)
• Diana Heller (1)
• Diana Jeffery (1)
• Diane Portman (2)
• Dianne Spillman (1)
• diarrhea (2)
• Diego Davis-Olegário (1)
• diet (2)
• dietary intervention (1)
• Dieter Hoelzer (1)
• diffuse large B cell (1)
• diffuse large B cell lymphoma (11)
• diffuse large B-cell lymphoma (15)
• diffuse midline glioma (1)
• dignicap (1)
• Dimas Padilla (1)
• direct oral anticoagulants (1)
• direct-to-patient (1)
• discontinuing therapy (1)
• discontinuing treatment (1)
• disease burden (1)
• disease control (1)
• disease heterogeneity (1)
• disease imaging (1)
• disease management (1)
• disease outcomes (1)
• disease progression (8)
• disease recurrence (4)
• disease staging (1)
• disease survival (1)
• disease-free survival (5)
• disparities (1)
• distant cancer recurrence (1)
• distant disease (1)
• distant disease–free survival (1)
• distant lesions (1)
• distant metastasis-free survival (1)
• distress (7)
• distress screening (2)
• distress thermometer (2)
• diversity (1)
• DLBCL (23)
• DLL-3 (3)
• DNA alteration (1)
• DNA damage (1)
• DNA damage repair deficiencies (1)
• DNA damage-repair pathway (1)
• DNA mistmatch repair (1)
• DNA repair (2)
• DOACs (2)
• docetaxel (31)
• docetaxel monotherapy (1)
• doctor-patient behavior (1)
• Domenica Lorusso (1)
• Don Stranathan (1)
• Donald Abrams (1)
• Donald Garrity (1)
• Donald I. Abrams (1)
• Donald L. Trump (1)
• Dong Wook Shin (1)
• Donna Bell (1)
• Donna Chen (1)
• Donna Fernandez (1)
• Donna Piunt (1)
• Dori Klemanski (1)
• Dorothy Lombe (2)
• Dorothy Turner (1)
• dosage (2)
• dose (1)
• dose decrease (1)
• dose de-escalation (1)
• dose density (1)
• dose escalation (3)
• dose fractionation (1)
• dose intensity (1)
• dose lowering (1)
• dose reduction (1)
• dose response (1)
• dose-dense chemotherapy (1)
• double-expressor lymphoma (1)
• double-hit lymphoma (1)
• doublet (1)
• Douglas Arthur (1)
• Douglas B. Johnson (2)
• Douglas Lowy (1)
• Douglas Wood (3)
• doxorubicin (8)
• driver mutations (1)
• droplet digital PCR (1)
• drug approvals (1)
• drug combination (1)
• drug conjugates (1)
• drug costs (1)
• drug development (3)
• drug disparities (1)
• drug indications (1)
• dry mouth (1)
• ductal carcinoma in situ (5)
• Duke Cancer Center (3)
• Duke Cancer Insitute (1)
• Duke Cancer Institute (4)
• Duke Medical Center (1)
• Duke University (7)
• duloxetine (1)
• Dung Le (6)
• duration of treatment (1)
• durvalumab (8)
• duvelisib (1)
• E. David Crawford (4)
• E. George Elias (3)
• E7208 trial (1)
• early breast cancer (10)
• early cancer detection (1)
• early CDT (1)
• early detection (5)
• early distant recurrence (1)
• early menopause (1)
• early palliative care (3)
• early referral (1)
• early relapsing (1)
• early salvage radiotherapy (1)
• early stage (2)
• early stage breast cancer (2)
• early stage lung cancer (1)
• early toxicity (1)
• early-phase trials (1)
• early-stage (3)
• early-stage breast cancer (7)
• early-stage cancer (1)
• early-stage diagnosis (1)
• early-stage disease (1)
• ease of use (1)
• Eastern Europe (1)
• EBCTCG (1)
• ebrt (1)
• ECC 2015 (29)
• ECCO (1)
• ECCO 2015 (2)
• ECHELON-1 trial (1)
• ECHELON-2 (1)
• ECOG (1)
• ECOG 1505 (1)
• ECOG ACRIN 2511 (1)
• ECOG-ACRIN (1)
• ecog-acrin 5508 (1)
• Ed Giampietro (1)
• edith a. perez (1)
• Edith Perez (4)
• Edmond Ang (1)
• Edoardo Francini (1)
• Eduardo Bruera (6)
• Eduardo Cazap (4)
• Eduardo L. Cazap (1)
• Edvardas Kaminskas (1)
• Edward Garon (1)
• Edward George (1)
• Edward Kim (1)
• Edward Romond (1)
• efficacy (3)
• EFGR mutation (1)
• EGFR (7)
• EGFR inhibitor (1)
• EGFR mutation (8)
• EGFR positive (1)
• EGFR resistance (1)
• EGFR signaling (1)
• EGFR T709M (1)
• egfr tki (1)
• EGFR+ NSCLC (1)
• EHA25 Virtual (10)
• Eileen Danaher Hacker (1)
• Eileen M. O'Reilly (1)
• Eileen O'Reilly (2)
• elderly (1)
• elderly patient (2)
• elderly patients (1)
• e-learning (1)
• elective nodal irradiation (1)
• Electra Paskett (4)
• electronic medical records (1)
• electronic support (1)
• electronic symptom monitoring (1)
• electronic tools (1)
• electroporation (1)
• Elena Elimova (1)
• Eleni Efstathiou (1)
• elevate tn (1)
• elevated PSA (1)
• Eli Lilly (1)
• Elias Jabbour (1)
• Elias Zahalka (1)
• Eliezer Robinson (3)
• Eliezer Van Allen (2)
• Elihu Estey (2)
• ELIZA A. HAWKES (1)
• Elizabeth A. Comen (1)
• Elizabeth Gerstner (1)
• Elizabeth Kessler (1)
• Elizabeth L. Travis (1)
• Elizabeth Mittendorf (1)
• Elizabeth Plimack (1)
• Elizabeth Reed (1)
• Elizabeth Shpall (1)
• Elizabeth Simmons (1)
• Ella Muller (1)
• Ellen Miller-Sonet (1)
• Ellen Sigal (4)
• Ellin Berman (1)
• ELOQUENT-2 (1)
• elotozumab (1)
• elotuzumab (3)
• embryo (1)
• emergency department (2)
• emergency department costs (1)
• emergency department use (1)
• emergency surgery (1)
• emerging therapies (1)
• emetic (1)
• emetogenic (2)
• emetogenic chemotherapy (1)
• Emil J. Freireich (3)
• Emily A. Kuhl (3)
• Emily Castellanos (1)
• Emily Dumler (1)
• Emily Haozous (1)
• Emily Kuhl (21)
• Emily Tonorezos (2)
• Emily Zurbuchen (1)
• Emma Hall (1)
• Emory (1)
• Emory Kinship Cancer Institute (1)
• Emory University (11)
• Emory University School of Medic (4)
• emphysema (2)
• EMR (1)
• EMRs (1)
• ENABLE model (1)
• encequidar (1)
• encorafenib (2)
• end of life (5)
• endocrine resistance (1)
• endocrine side effects (1)
• endocrine therapy (16)
• endocrine therapy-resistant (1)
• endocrine treatment (1)
• endocrine-based therapy (1)
• end-of-life (3)
• end-of-life care (8)
• end-of-life issues (1)
• endometrial cancer (4)
• EndoPredict (1)
• endoscopy (1)
• endothelial function (2)
• enestop (1)
• enfortumab vedotin (1)
• ENGOT-OV16 NOVA (1)
• ENGOT-OV16/NOVA (1)
• enhanced quality (1)
• Enrica Marchi (1)
• Enrique Soto Perez-de-Celis (2)
• enzaludamide (3)
• enzalutamide (14)
• EnzaMet (1)
• enzamet trial (1)
• EnzaRad (1)
• EORTC (2)
• EORTC 18071 (1)
• EORTC 90101 CREATE (1)
• epacadostat (1)
• ePAL (1)
• ependymoma (1)
• epidemiology (1)
• epidemiology in younger patients (1)
• epirubicin (2)
• epithelial ovarian cancer (5)
• EPOCH-R (1)
• eprirubicin (2)
• equality (1)
• ER visits (1)
• ER+ (1)
• ER+ breast cancer (5)
• ER+ metastatic (1)
• ER+/HER2– (1)
• Erasmus University (1)
• erectile function (1)
• eribulin (1)
• Eric Bouffet (1)
• Eric Francois (4)
• Eric Genden (1)
• Eric Jonasch (3)
• Eric Lax (1)
• Eric Lim (2)
• Eric Lis (1)
• Eric M. Horwitz (1)
• Eric Pujade-Lauraine (1)
• Eric Roeland (10)
• Eric S. Zhou (1)
• Eric Van Cutsem (2)
• Eric Winer (4)
• Eric Wisotzky (1)
• Erica Kaye (1)
• Erica Mayer (2)
• Erich Sturgis (1)
• Erika Hamilton (1)
• Erika Ramsdale (1)
• Erin Hahn (2)
• Erin Van Blarigan (1)
• erlotinib (6)
• Ernest Greenberg (2)
• Ernest Hawk (3)
• ER-positive (5)
• ER-positive breast cancer (1)
• ER-positive metastatic breast ca (1)
• ESMO (28)
• ESMO 16 (3)
• ESMO 2015 (1)
• ESMO 2016 (42)
• ESMO 2017 (23)
• ESMO 2018 (21)
• esmo 2020 (20)
• esophageal adenocarcinoma (1)
• esophageal cancer (12)
• esophageal carcinoma (1)
• esophageal squamous cell carcino (1)
• esophagectomy (2)
• ESPAC-4 trial (1)
• ESR1 mutation (1)
• estrogen (1)
• estrogen deprivation (1)
• estrogen receptor (2)
• estrogen receptor 1 (1)
• estrogen receptor positive (3)
• estrogen receptor-positive (9)
• estrogen-receptor positive (2)
• Ethan Basch (4)
• Ethan Dmitrovsky (2)
• ethics (2)
• ethnicity (1)
• Etienne Brain (1)
• etoposide (2)
• Eugene Tombler (6)
• Eugenie Spiguel (4)
• Eurocare (1)
• Europe (1)
• European Cancer Congress 2015 (1)
• European Institute of Oncology (1)
• European Medicines Agency (1)
• European Myeloma Network Trial (2)
• European Union (1)
• euthanasia (1)
• Eva Joseph (1)
• Eva Pendleton (1)
• Evan Lipson (2)
• Evangelia Razis (1)
• Everett Vokes (4)
• everolimus (12)
• evidence (1)
• evidence-based (1)
• Example (1)
• exemestane (4)
• exercise (4)
• exercise intervention (1)
• exercise oncology (1)
• exome sequencing (1)
• exon 14 (1)
• exon 18 (1)
• exon 19 (1)
• exon 20 (1)
• exon 21 (1)
• exon skipping (1)
• expanded access (2)
• experimental treatment (1)
• ExteNET trial (1)
• extensive-stage sclc (1)
• external beam (1)
• external beam radiation (1)
• external-beam radiation (1)
• extrahepatic disease (2)
• extreme hypofractionation (1)
• EZH2 (1)
• Ezra Cohen (1)
• F. Owen Hoffman (5)
• Fabiana Passoni (1)
• Fabrice Barlesi (2)
• Fabrice Denis (2)
• facility volume (1)
• FACP (1)
• FACS trial (1)
• FADI G. HADDAD (1)
• FADILA KOUHEN (1)
• Fadlo Khuri (1)
• FALCON trial (1)
• fallopian tube cancer (3)
• familial cancer risk (1)
• families (1)
• family and patient outcomes (1)
• family caregivers (1)
• family centered care (1)
• family history (1)
• Farhad Ravandi (9)
• FASCO (2)
• FASCO; CLIFFORD A. HUDIS (1)
• FAST trial (3)
• fat (1)
• fatigue (7)
• fatigue score (1)
• FATIMA REZZOUG (1)
• Fatima Rizvi (1)
• FC Rad Onc (SA) (1)
• FCR (1)
• FCS (SA) (1)
• Fc-receptor polymorphism (2)
• FDA (5)
• FDA approval (1)
• FDA approvals (1)
• fda oncology center of excellence (1)
• fear of recurrence (2)
• fears (1)
• feasibility (1)
• febrile neutropenia (1)
• FEC 100 (1)
• federal government (2)
• federal law (1)
• Federico Cappuzzo (2)
• female leadership (1)
• female patients (1)
• female survivors (1)
• fergi trial (1)
• FERGIE trial (1)
• Fernando Diaz (1)
• fertility (2)
• fertility preservation (3)
• fertility-sparing surgery (1)
• fertility-sparing treatment (1)
• fetal development (1)
• FGFR (2)
• FGFR inhibitor (1)
• FGFR3 (1)
• fibrosis (1)
• Filippo Spreafico (1)
• financial burden (1)
• financial guidance (1)
• financial intervention (1)
• financial toxicities (1)
• financial toxicity (3)
• Fiona Damstra (1)
• fire-3 trial (1)
• first complete remission (1)
• first study (1)
• FIRSTANA (1)
• first-line chemotherapy (1)
• first-line hormone therapy (1)
• first-line therapy (11)
• first-line treatment (4)
• FISH (1)
• FISH data (1)
• fitness (1)
• fixed duration (1)
• FLASH (1)
• FLASH study (1)
• Flatiron Health (1)
• FLAURA (1)
• flaura trial (1)
• FLORIAN LORDICK (1)
• Florida International University (1)
• FLOT4-AIO trial (1)
• FLT3 (2)
• FLT3-ITD (1)
• fludarabine (3)
• fluoropyrimidine (2)
• fluorouracil (5)
• fnf-004 trial (1)
• focus group (1)
• FOLFIRI (1)
• FOLFIRI-bevacizumab (2)
• FOLFIRINOX (3)
• FOLFOX (2)
• folfoxiri (1)
• follicular lymphoma (18)
• follow-up care (1)
• follow-up scans (1)
• Forte trial (2)
• FORWARD II (1)
• fosaprepitant (2)
• Fox Chase (6)
• Fox Chase Cancer Center (7)
• fractionation (3)
• fractionation schedule (1)
• frailty (1)
• Fran Visco (1)
• Francis Crick Institute (3)
• Francis Lévi (1)
• Francis Paul Worden (2)
• Francis S. Collins (1)
• Francisco J. Esteva (1)
• Franck Morschhauser (1)
• Franco Cavalli (1)
• Franco Muggia (2)
• Frank Sierawski (1)
• Fred Hirsch (9)
• Fred Hutch (2)
• Fred Hutch Cancer Center (2)
• Fred Hutchinson (5)
• Fred Hutchinson Cancer Center (2)
• Fred Hutchinson Cancer Research (1)
• Fred Hutchinson Cancer Research Center (2)
• Fred Huthinson (1)
• Fred R. Hirsch (1)
• Fred Saad (6)
• Frederic Amant (2)
• Frederic Grannis (1)
• Frederic Ivan Leong Ting (1)
• Frederick Appelbaum (3)
• Frederick Behm (1)
• Fredrick B. Hagemeister (1)
• freedom from distant recurrence (1)
• French FILO Group (1)
• Fritz Schröder (2)
• front-line treatment (1)
• fulvestrant (12)
• Fumiko Chino (1)
• function ability (1)
• futile care (1)
• futile treatment (1)
• G.S. Raju (1)
• Gabriel Hortobagyi (2)
• gabriel lopez (1)
• Gabriele Roden (1)
• Gabrielle Rocque (1)
• GADOLIN (3)
• Gail Flores (6)
• GALLIUM trial (1)
• gamma-1 study (1)
• Ganesh Shankar (1)
• gap in access (1)
• GARTH STROHBEHN (1)
• Gary Deng (9)
• Gary H. Lyman (3)
• Gary Onik (1)
• Gary Rodin (1)
• Gary Steele (1)
• Gary Whitman (1)
• Gary Winkel (1)
• gastrectomy (1)
• gastric adenocarcinoma (3)
• gastric cancer (16)
• Gastric Cancer (1)
• gastric junction adenocarcinoma (1)
• gastric junction cancer (1)
• gastroesophageal adenocarcinoma (3)
• gastroesophageal cancer (2)
• Gastroesophageal Cancer (9)
• gastroesophageal junction (1)
• gastroesophageal junction adenoc (2)
• gastroesophageal junction cancer (2)
• gastrointestinal cancer (20)
• Gastrointestinal Cancer (11)
• gastrointestinal cancers (1)
• Gastrointestinal Cancers Symposi (15)
• gastrointestinal side effects (1)
• gastrointestinal tract (1)
• Gautam Mehta (1)
• gBRCA mutation (1)
• gc4419 (1)
• G-CSF (1)
• gefitnib (2)
• geftinib (3)
• GEJ adenocarcinoma (1)
• gej cancer (3)
• gemcitabine (18)
• Gemelli University Hospital (1)
• GEMOX (1)
• GEN503 clinical trial (1)
• gender (1)
• gene alterations (1)
• gene biomarkers (1)
• Gene Bishop (1)
• gene expression (3)
• gene expression profiling (1)
• gene recurrence score (2)
• gene signature (1)
• gene therapy (1)
• gene-expression model (1)
• generic drugs (1)
• genetic alterations (1)
• genetic information (1)
• genetic mutation (1)
• genetic mutations (2)
• genetic phenotype (1)
• genetic predisposition (1)
• genetic sequencing (2)
• genetic testing (3)
• genetic variants (1)
• genetics (12)
• genitourinary cancer (17)
• Genitourinary Cancers Symposium (35)
• genitourinary oncology (1)
• genome-wide sequencing (1)
• genomic (1)
• genomic alterations (2)
• genomic analysis (2)
• genomic characterization (1)
• genomic data (1)
• Genomic Health (1)
• genomic profiling (2)
• genomic risk (1)
• genomic screening (1)
• genomic sequencing (3)
• genomic studies (1)
• genomic test (1)
• genomic testing (2)
• genomic tests (1)
• genomic therapy (1)
• genomics (11)
• Genomics/Genetics (7)
• genotyping (1)
• Geoffrey I. Shapiro (1)
• Geoffrey Ku (1)
• Geoffrey R. Oxnard (2)
• George Bosl (1)
• George Canellos (2)
• George Sledge (2)
• George Somlo (1)
• George Washington University (2)
• Georgetown (1)
• Georgetown University (8)
• Georgia Cancer Center (1)
• GeparNuevo (1)
• GeparSixto (1)
• Geraldine Carroll (5)
• Gerard Morton (1)
• Gerdes (1)
• Gerhardt Attard (1)
• geriatric assessment (1)
• geriatric assessments (1)
• geriatric oncology (13)
• Geriatric Oncology (2)
• geriatric patients (2)
• geriatric survivorship (1)
• geriatrician (1)
• geriatrics (1)
• germ cell tumor (2)
• German Breast Group (4)
• germline BRCA mutation (1)
• germline BRCA ovarian cancer (1)
• germline mutation (3)
• germline testing (1)
• GETUG-AFU 16 (1)
• Gevorg Tamamyan (1)
• Ghassan Abou-Alfa (1)
• GI cancer (3)
• gi cancers symposium (26)
• GI Cancers Symposium 2017 (18)
• Gideon Blumenthal (2)
• Gideon Michael Blumenthal (1)
• Gilbert Lawrence (3)
• Gilberto Lopes (3)
• Gilead 115 (1)
• gilteritinib (1)
• Gini Fleming (1)
• Giorgio Scagliotti (3)
• Giuseppe Del Priore (1)
• glasdegib (1)
• Gleason score (1)
• glioblastoma (2)
• glioma (1)
• global access (1)
• global access to drugs (1)
• global cancer burden (1)
• global cancer care (3)
• Global Cancer Care (2)
• global cancer disparities (1)
• global health (1)
• global health care (1)
• global health costs (1)
• global oncology (2)
• global qol (1)
• global standards (1)
• glottic cancer (1)
• glycan (1)
• glycochip (1)
• glycomics (1)
• gm-csf (1)
• GOLD trial (1)
• gonadotropin-releasing hormone a (1)
• Gopal Gupta (1)
• Gordon Schiff (1)
• goserelin (1)
• Gouri Shankar Bhattacharyya (1)
• government healthcare (1)
• Govind Persad (12)
• GOYA trial (1)
• Graall-R 2005 study (1)
• Grace Wang (1)
• grade (1)
• grading tumors (1)
• graft vs host disease (1)
• graft-versus-host-disease (1)
• graft-vs-host-disease (1)
• Graham A. Colditz (2)
• Graham Watson (1)
• Grant Achatz (1)
• Grant R. Williams (1)
• gray zone lymphoma (2)
• grbca (1)
• Greg Judy (1)
• Gregory Armstrong (4)
• Gregory Bociek (1)
• Gregory H. Jones (1)
• Gregory Otterson (1)
• Greta Stifel (1)
• grey zone lymphoma (1)
• gross total resection (1)
• gu cancers symposium (16)
• GU Cancers Symposium 2017 (21)
• gu cancers symposium, 5FU, mitomycin, chemotherapy, radiation therapy, MIBC, muscle-invasive bladder cancer (1)
• gu cancers symposium, cost of care, abiraterone, ADT, androgen-deprivation therapy, qol, survival, stampede trial (1)
• gu cancers symposium, crpc, immunotherapy, tki, monoclonal antibody (1)
• gu cancers symposium, doublet, triplet, RCC, kidney cancer, renal cell carcinoma, immunotherapy (1)
• GU Symposium 2016 (18)
• guadecitabine (1)
• guidance statement (1)
• guideline (1)
• guidelines (6)
• Guido Marcucci (1)
• Guneet Walla (1)
• Gunter von Minckwitz (5)
• Gurpreet Rooprai (1)
• Guru Sonpavde (1)
• Gustave Roussy (11)
• Guy’s and St. Thomas’ Hospital (1)
• GVHD (3)
• Gwendolyn Quinn (1)
• gynecologic cancer (3)
• gynecologic cancers (6)
• Gynecologic Cancers (22)
• H. Jack West (1)
• H. Lee Moffitt Cancer Center (7)
• h3b-8800 (1)
• HAGAR ELGHAZAWY (1)
• Hagop Kantarjian (24)
• HAGOP M. KANTARJIAN (1)
• hair loss (2)
• hairy cell leukemia (1)
• Haiti (1)
• halting treatment (1)
• Hamilton Health Sciences (1)
• Hamza Hashmi (2)
• handgrip test (1)
• Hannah Dzimitrowicz (1)
• Hannah Stewart (9)
• Hans Gerdes (1)
• Hans Wildiers (2)
• Hans-Joerg Hammers (2)
• haploidentical transplantation (1)
• Harefield Hospital (1)
• Harold Burstein (8)
• Harold J. Burstein MD (1)
• Harriet Gross (1)
• Harry Bear (3)
• harry d. bear (2)
• Harry Erba (1)
• Harvard Medical School (5)
• Harvey J. Cohen (1)
• Hassan Errihani (2)
• HAYLEY ARCENEAUX (1)
• HCC (6)
• head and neck (1)
• head and neck cancer (21)
• Head and Neck Cancer (8)
• head and neck cancers symposium (9)
• head and neck melanoma (2)
• head and neck squamous cell carcinoma (1)
• head and neck symposium (1)
• health care delivery research (1)
• health care disparities (6)
• health care provider (1)
• health care utilization (1)
• health disparities (2)
• health justice (3)
• health outcomes (1)
• health system (1)
• health technology (1)
• health-care (5)
• health-care application (1)
• healthcare costs (1)
• health-care costs (1)
• healthcare delivery (1)
• health-care delivery (1)
• health-care policy (2)
• Health-Care Policy (2)
• healthcare system (1)
• health-care technology (1)
• heart disease (2)
• heart dose (1)
• Heather Greenlee (1)
• HEATHER McARTHUR (1)
• Heather Sook Han (1)
• Heather Thompson Buum (1)
• Heather Wakelee (4)
• hedgehog pathway inhibitor (1)
• Heiddis Valdimarsdottir (1)
• Heidi Klepin (1)
• Heikki Joensuu (1)
• Heinz-Josef Lenz (6)
• Helen Ma (1)
• Helen MacKay (2)
• Helper (1)
• hematologic (1)
• hematologic malignancies (7)
• Hematologic Malignancies (5)
• hematologic malignancy (3)
• hematology (16)
• hematopoietic cell transplantati (1)
• Heniz-Josef Lenz (1)
• Henry Ford Cancer Center (1)
• Henry Ford Health (1)
• Henry Lynch (1)
• heparin-induced thrombocytopenia (1)
• hepatobiliary cancer (3)
• Hepatobiliary Cancer (9)
• hepatocellular carcinoma (18)
• her2 (1)
• HER2- (2)
• HER2 blockade (2)
• HER2- breast cancer (3)
• her2 low (1)
• her2 mutations (1)
• HER2 negative (3)
• HER-2 negative (1)
• HER2 positive (3)
• HER2 status (1)
• her2 tki (1)
• HER2/neu gene (1)
• HER2+ breast cancer (6)
• her2climb (1)
• HER2-directed therapy (1)
• her2-e (1)
• HER2-negative (23)
• HER2-negative breast cancer (1)
• HER2-positive (15)
• HER2-positive breast cancer (6)
• HER2-targeted treatment (1)
• her3 (1)
• hera trial (1)
• HERACLES (1)
• Herbert Irving Cancer Center (1)
• hereditary breast cancer (1)
• hereditary multigene panels (1)
• hereditary test (1)
• Hernan Barangan (1)
• heterogeneity (2)
• HFRT (1)
• HGBCL (1)
• HIF2A (1)
• high quality care (1)
• high risk of dying (1)
• high tumor burden (1)
• high-dose interferon-α2b (2)
• high-dose methotrexate (2)
• high-dose radiation (1)
• high-dose radiotherapy (1)
• high-grade B cell lymphoma (1)
• high-grade serous ovarian cancer (1)
• highlights (2)
• high-risk (2)
• high-risk breast cancer (2)
• high-risk disease (2)
• high-risk head and neck cancer (2)
• high-risk lung cancer (2)
• high-risk myeloma (1)
• high-risk neuroblastoma (1)
• high-risk node negative (1)
• high-risk patients (1)
• high-risk prostate cancer (5)
• high-risk renal cell carcinoma (2)
• high-volume centers (3)
• high-volume prostate cancer (1)
• Hilary Adams (4)
• Hilary Gan (1)
• Hillard Lazarus (2)
• Hind Rafei (1)
• hippocampus (1)
• Hispanic (1)
• Hispanic breast cancer (1)
• histology (1)
• history of addiction (1)
• HIV (1)
• HL (1)
• hla (1)
• HNSCC (3)
• Hodgkin lymphoma (15)
• Holger Lode (2)
• Holly Lawson (1)
• homeless patients (1)
• homologous recombination deficiency (1)
• Hong Kong (1)
• HOPE CRAIG (13)
• Hope Haefner (1)
• Hope Rugo (12)
• hope s. rugo (2)
• hopelessness (1)
• hopes (1)
• Hôpital de Hautepierre (1)
• Hôpital Henri Mondor (1)
• Hôpital Hôtel-Dieu (1)
• Hôpital Le Bocage (2)
• Hôpital Saint-Antoine (1)
• Hôpital Saint-Louis (2)
• hormonal therapy (3)
• hormone naive prostate cancer (1)
• hormone receptive (1)
• hormone receptor (1)
• hormone receptor positive (6)
• hormone receptor status (1)
• hormone receptor-positive (7)
• hormone receptor–positive (3)
• hormone receptor-positive breast (1)
• hormone replacement (1)
• hormone status (1)
• hormone therapy (2)
• hormone therapy naive (1)
• hormone treatment (1)
• hormone-naive disease (1)
• hormones (1)
• hormone-sensitive (3)
• hormonotherapy (1)
• hospice (2)
• hospice care (2)
• hospice referrals (1)
• hospital admission (1)
• hospital readmission (1)
• Hospital Universitario 12 De Oct (4)
• hospitalizations (1)
• hot flashes (2)
• HOVON-Nordic Lymphoma Group (1)
• Howard Burris (3)
• Howard Chazin (1)
• Howard Kaufman (1)
• Howard Sandler (8)
• Howard Scher (3)
• Howard West (2)
• HPV (9)
• HPV vaccine (3)
• HPV-16 (1)
• HPV-16 vaccine (1)
• HPV-associated oropharyngeal squ (1)
• HPV-positive oropharyngeal cance (1)
• HR positive (1)
• HR+ (1)
• HR+ breast cancer (3)
• HR+/HER2- (1)
• HR+/HER2+ (2)
• HR-positive (6)
• HR-positive breast cancer (2)
• Humaid Al-Shamsi (1)
• human error (1)
• human leukocyte antigen (1)
• human papillomavirus (9)
• humanitarian (1)
• Huntsman Cancer Institute (6)
• hyaluronidase (1)
• hydrogel spacer (1)
• Hyo Jin Ru (1)
• hyperglycemia (1)
• hypertension (2)
• hyperthermic intraperitoneal (1)
• hyperthermic intraperitoneal che (1)
• hyperthermic intraperitoneal chemotherapy (1)
• hypocalcemia (1)
• hypofractionated (5)
• hypofractioned radiotherapy (4)
• hypomethylating agent (1)
• hypomethylating agents (1)
• HYPO-RT-PC trial (1)
• hypoxia (1)
• hypoxia-inducible factor 2 alpha (1)
• hyprofractioned radiation (1)
• hysterectomy (1)
• IAEA trial (1)
• IALSC 2015 (2)
• Ian Chau (1)
• ian e. krop (1)
• Ian Krop (2)
• Ian Yarett (6)
• IASLC 2015 (22)
• ibandronate (3)
• Ibiayi Dagogo-Jack (1)
• IBIS-1 study (1)
• ibis-i trial (1)
• ibis-ii (1)
• ibrutinib (17)
• ibrutinib resistance (1)
• Icahn Mount Sinai School of Medi (1)
• Icahn School of Medicine (1)
• iCanCare study (1)
• icaria-mm (1)
• ice trial (1)
• ICLIO (3)
• ICON6 trial (1)
• ICON8 trial (2)
• idarubicin (1)
• IDEA collaboration (1)
• IDEA trial (2)
• IDEAL trial (1)
• idelalisib (2)
• idh1 (1)
• IDMC (1)
• IFCT-1501 MAPS2 trial (2)
• ifofsamide (1)
• IGF/insulin signaling (1)
• IGFR (1)
• Ignacio Melero (4)
• IGRT (1)
• IMAB362 (1)
• image-guided (1)
• image-guided radiotherapy (1)
• imaging (2)
• imaging technique (1)
• imetelstat (1)
• immediate surgery (1)
• IMmotion 151 (3)
• IMMU-132 (1)
• immune biomarker (1)
• immune cells (3)
• immune checkpoint (2)
• immune checkpoint blockade (3)
• immune checkpoint blockers (1)
• immune checkpoint inhibitor (2)
• immune checkpoint inhibitors (10)
• immune dysfunction (1)
• immune inhibitors (1)
• immune microenvironment (2)
• immune response (2)
• immune system (1)
• immune therapies (1)
• immune thrombocytopenia (1)
• immune-related (1)
• immune-related adverse events (2)
• immunity (1)
• immunochemotherapy (3)
• immunogenic (2)
• immunogenic MSI tumor (1)
• immunohistochemistry (1)
• immunology (2)
• immunomodulatory agents (1)
• immuno-oncology (19)
• immunoregulatory inhibition (1)
• immunoscore (1)
• immunosignatures (1)
• immunotherapeutics (1)
• immunotherapies (1)
• immunotherapy (169)
• Immunotherapy (92)
• immunotherpy (1)
• IMO Clinique de Genolier (1)
• IMPACT study (1)
• IMpassion 130 (2)
• Imperial College London (1)
• IMpower 130 (1)
• IMpower131 trial (1)
• improved quality of life (1)
• improved survival (1)
• improved workflow (1)
• improving cancer care (1)
• improving outcomes (1)
• IMPT (1)
• IMRT (7)
• imspire170 (1)
• IMvigor (1)
• IMvigor 211 (1)
• imvigor130 (1)
• IMvigor210 trial (1)
• in situ vaccine (1)
• in-breast recurrence (1)
• inclusion criteria (2)
• Indiana University (1)
• Indiana University Simon Cancer (2)
• individualized treatment (1)
• indolent lymphoma (1)
• indolent lymphomas (1)
• indolent NHL (1)
• indolent non-Hodgkin lymphoma (1)
• induction (2)
• induction BCG therapy (1)
• induction chemotherapy (1)
• induction radiotherapy (1)
• induction therapy (2)
• induction treatment (1)
• inequality of care (1)
• infectious disease (2)
• inflammation (2)
• inflammatory breast cancer (2)
• infrastructure (1)
• Inga Lennes (1)
• Ingrid Mayer (3)
• inhibitory receptor expression (1)
• initial therapy (2)
• inotuzumab (2)
• inotuzumab ozogamicin (1)
• INSERM (4)
• insomnia (2)
• Institut Curie (1)
• Institut Curies (1)
• Institut Gustave Roussy (8)
• Institut Jules Bordet (1)
• Institut Régional du Cancer (1)
• Institute for Clinical Evaluativ (1)
• Institute of Cancer Research (3)
• Institute of Cancer Research Lon (1)
• Institute of Clinical Cancer Res (1)
• Institute of Medicine (1)
• Institute of Medicine report (1)
• Instituto Nazionale Tumori-Fonda (2)
• insulin (1)
• insurance (1)
• integrated care (1)
• integrating palliative care (1)
• integration of palliative care (2)
• intensity modulated proton thera (1)
• intensity-modulated (1)
• intensity-modulated radiotherapy (1)
• intensive chemotherapy (1)
• interaperitoneal (1)
• interferon gamma (1)
• interleukin 12 (1)
• intermediate-risk (2)
• intermediate-risk prostate cance (1)
• international oncology (3)
• international standards (1)
• interpretation (1)
• intervention (1)
• interventional (1)
• intracranial disease (1)
• intracranial response (2)
• intraoperative peritoneal lavage (1)
• intraperitoneal (1)
• intraperitoneal chemotherapy (2)
• intraperitoneal immunotherapy (1)
• intratumoral (1)
• intravascular DLBCL (1)
• intravenous (1)
• intravenous chemotherapy (2)
• intrinsic expression subtype (1)
• invasive breast cancer (2)
• investigator-choice chemotherapy (1)
• involved field irradiation (1)
• ipatasertib (1)
• ipilimumab (27)
• ipilimumab-refractory (1)
• ipilumumab (5)
• IPOS APOS 2015 (6)
• IPOS-APOS 2015 (11)
• IPOS-APOS 2015. Andrea Patenaude (1)
• Ira Byock (1)
• Irad Deutsch (1)
• iRAE (2)
• Irene Higginson (2)
• irinotecan (4)
• IROCK study (1)
• ISA101 (1)
• Isabel Arrellaga-Romany (1)
• Isacco Montroni (1)
• isatuximab (1)
• ischemic stroke (1)
• Ishwaria M. Subbiah (1)
• Ismail Jatoi (3)
• Issues in Oncology (18)
• Istituto Nazionale dei Tumori (4)
• Istituto Toscano Tumori-Ospedale (1)
• italy (1)
• iv paclitaxel (1)
• ivosidenib (1)
• IVY DUNEIER (1)
• IWWD.org (1)
• ixabepilone (1)
• ixazomib (3)
• J. Gregory Mears (1)
• J. Nicholas Dionne-Odom (1)
• Jaafar Bennouna (1)
• Jacek Jassem (2)
• Jack B. Fu (1)
• Jack Cuzick (4)
• Jack Gentile (1)
• Jack Lambert (1)
• Jacob Laubach (1)
• Jacob Rowe (1)
• Jacob Strand (1)
• Jaffer Ajani (2)
• JAK inhibitor (2)
• JAK2 inhibitor (1)
• Jame Abraham (21)
• James A. Stewart (1)
• James Abbruzzese (3)
• James Armitage (26)
• James Armitage Hagop Kantarjian (1)
• James Berenson (1)
• James Cancer Center (1)
• James Cancer Hospital (1)
• James Cleary (1)
• James Doroshow (2)
• James F. Holland (3)
• James Foran (2)
• James Gould (1)
• James Hillard (1)
• James Jett (2)
• James Kochenderfer (4)
• James Mohler (1)
• James Mulshine (10)
• James O. Armitage (3)
• James P. Stevenson (1)
• James Perry (1)
• James Rubenstein (1)
• James Smithy (1)
• James W. Lynch (1)
• James Yu (2)
• Jamie H. Von Roenn (1)
• Jamie Jacobs (1)
• Jamil Aliyev (1)
• Jamil Rivers (1)
• Jan Buckner (2)
• Jan Oosterwijk (1)
• Jane Greene (1)
• Jane Gutkovich (2)
• Jane McNeil Beith (1)
• Jane Winter (1)
• Janessa Laskin (1)
• Janet Klein (1)
• Janet Snapp (1)
• Janet Weinberg (1)
• Janet Wohlmacher (1)
• Janice Dutcher (1)
• Janine Overcash (5)
• Japan Clinical Oncology Group (1)
• Jasenka Piljac Žegarac (9)
• Jasmine M. Wong (1)
• Jason Gotlib (1)
• Jason Zimmermann (1)
• JAVELIN (1)
• javelin renal 101 (1)
• JAVELIN study (1)
• Javier Cortes (1)
• Jay Harris (5)
• Jay R. Harris (1)
• JCOG1001 (1)
• JD (1)
• Jean Connors (1)
• Jean M. Connors (5)
• Jean-Charles Soria (6)
• Jean-Michel Hannoun-Levi (1)
• JEANNETTE PARKES (1)
• Jeannine Nonaillada (1)
• Jeannine Walston (1)
• Jean-Yves Douillard (2)
• Jedd Wolchok (6)
• Jeff Boyd (1)
• Jeff Dunn (4)
• Jeff Summers (1)
• Jeffrey Bradley (1)
• Jeffrey Crawford (1)
• Jeffrey Groeger (1)
• Jeffrey Jones (1)
• Jeffrey Lancet (1)
• Jeffrey Patton (1)
• Jeffrey Schneider (1)
• Jeffrey Weber (1)
• Jennifer Brown (2)
• Jennifer Brudno (1)
• Jennifer Gao (1)
• Jennifer Ho (1)
• Jennifer King (2)
• Jennifer Legible (1)
• Jennifer Ligibel (2)
• Jennifer Litton (1)
• Jennifer Lycette (2)
• Jennifer Mack (1)
• Jennifer Nam Choi (1)
• Jennifer Temel (4)
• Jennifer Titche (1)
• Jennifer Wargo (1)
• Jennifer Woyach (4)
• Jenny Ahlstrom (1)
• Jens Huober (1)
• Jenske Geerling (1)
• Jeong-Seon Ryu (1)
• Jerald Radich (5)
• Jerald Varner (1)
• Jeremy Hirst (1)
• Jeremy Hon (1)
• Jeremy Pivor (1)
• Jeremy Warner (1)
• Jeri Dyson (1)
• Jerome Yates (1)
• Jeromie Ballreich (1)
• Jesse McGreivy (1)
• Jessica Boehmer (1)
• Jessica Nye (1)
• Jessica Scott (2)
• Jessica Wu (1)
• Jesuel Padro-Guzman (1)
• Jill Lacy (1)
• Jim Armitage (2)
• Jim Mulshine (1)
• Jim Omel (2)
• Jim Taulman (1)
• Jim Turner (1)
• Jimmie Harvey (1)
• Jimmie Holland (7)
• Jinane Kharmoum (1)
• jipang trial (1)
• jo (1)
• Jo Cavallo (1106)
• Joachim Yahalom (1)
• Joanne Mortimer (2)
• Joanne Weidhaas (1)
• Jocelyn Ray (1)
• Jocelyn Solis-Moreira (2)
• Jodi MacLeod (1)
• Joel Tepper (2)
• John A. Thompson (1)
• John Cox (2)
• John F. Thompson (1)
• John Fracchia (1)
• John Gentile Jr (1)
• John Gerecitano (2)
• John Goodman (2)
• John Grecula (2)
• John Gribben (1)
• John H. Stewart (1)
• John Hainsworth (1)
• John Jakob (1)
• John L. Marshall (1)
• John Leonard (2)
• John Macdonald (1)
• John Marshall (10)
• John Neoptolemos (1)
• John Pagel (2)
• John Peters (1)
• John Primrose (1)
• John Smyth (12)
• John Suh (1)
• John Thompson (1)
• John Williams (1)
• JOHNNY BORGSTROM (1)
• Johns Hopkins (6)
• Johns Hopkins Bloomberg School o (1)
• Johns Hopkins Kimmel Cancer Center (1)
• Johns Hopkins Medicine (1)
• Johns Hopkins School of Medicine (1)
• Johns Hopkins Sidney Kimmel Cancer Center (1)
• Johns Hopkins University (3)
• Joke Bradt (2)
• Joleen Hubbard (1)
• Jonas de Souza (1)
• Jonathan Cohen (1)
• Jonathan Cotliar (2)
• Jonathan Friedberg (3)
• Jonathan L. Finlay (1)
• Jonathan Ledermann (2)
• Jonathan Lewis (1)
• Jonathan R. Strosberg (1)
• Jonathan Rosenberg (5)
• Jonathan Schwartz (3)
• Jonathan Strosberg (2)
• JONATHAN W. FRIEDBERG (1)
• Jonathon Cohen (2)
• Jordan Holmes (1)
• Jorg Dietrich (1)
• Jorge Cortes (3)
• Jorge Reis-Filho (1)
• Jose Karam (1)
• Jose Leis (1)
• Josep Llovet (2)
• Joseph B. Narus (1)
• Joseph Bailes (1)
• Joseph Connors (3)
• Joseph Cupolo (1)
• Joseph Greer (1)
• Joseph Jacobson (2)
• Joseph Mason (1)
• Joseph Simone (1)
• Joseph Sparano (4)
• Joseph V. Simone (1)
• Joseph V. Simone Award (2)
• Josh Mailman (1)
• Joshua Armenia (1)
• Joshua Brody (1)
• Joshua Drago (1)
• Joshua Lang (1)
• Joshua Spendlove (1)
• JOYCE KURISKO (1)
• Joyce Liu (2)
• Jr (1)
• Juan Chipollini (1)
• Juanita Crook (1)
• Judd Moul (1)
• Judith Balmana (2)
• Judith Malmgren (1)
• Judith Paice (3)
• Judith Vick (2)
• Judy Garber (5)
• Judy Perkins (1)
• Jules Bordet Institute (2)
• Julia Fehniger (1)
• Julia Rowland (2)
• Julia White (2)
• Julie A. Schneider (1)
• Julie Bryar Porter (1)
• Julie Bullock (1)
• Julie Gralow (6)
• Julie Lemieux (2)
• julie m. vose (3)
• Julie Miller (1)
• Julie Nangia (1)
• Julie Park (1)
• Julie Silver (1)
• Julie Vose (34)
• Julien Edeline (2)
• Julienne Bower (1)
• JULIET trial (1)
• Jun J. Mao (5)
• Jun Mao (13)
• Jung-min Lee (1)
• Justin Brown (1)
• Justin Gainor (1)
• Jyothirmai Gubili (71)
• K. Holly Mead (1)
• K. Simon Yeung (2)
• Kah Poh (Melissa) Loh (2)
• Kah Poh Melissa Loh (1)
• Kaiser Permanente (1)
• Kamal Menghrajani (1)
• Kamran Ahmed (1)
• Karen Colbert Maresso (1)
• Karen Daily (1)
• KAREN E. KNUDSEN (1)
• Karen Fasciano (2)
• Karen J. Krag (1)
• Karen Kelly (3)
• Karen Knudsen (1)
• Karen Lisa Smith (2)
• Karen Marcus (1)
• Karen Merlino (1)
• Karen Nestor (1)
• Karen Peterson (1)
• Karen Popkin (4)
• Karen Reckamp (1)
• Karen Winkfield (1)
• Karim Chamie (1)
• Karim Fizazi (4)
• Karim Touijer (1)
• Karl Lewis (1)
• Karl Schwartz (2)
• Karuna Ganesh (1)
• Karyn Goodman (1)
• Katarzyna Jerzak (1)
• kate2 (1)
• Katharina Fleischhauer (2)
• Katherine Crawford (2)
• Katherine Crew (1)
• Katherine H. Crawford (2)
• Katherine Reeder-Hayes (2)
• KATHERINE trial (1)
• Kathleen Bickel (1)
• Kathleen Cathcart (1)
• Kathleen Elizabeth Bickel (1)
• Kathleen Foley (2)
• Kathleen Moore (2)
• Kathleen Pritchard (2)
• Kathleen Ruddy (1)
• Kathleen Uhl (1)
• Kathleen Wesa (5)
• Katholieke Universiteit Leuven (1)
• Kathryn Desimone (1)
• Kathryn E. Hitchcock (1)
• Kathryn Hudson (1)
• Kathryn Mileham (1)
• Kathryn Roberts (1)
• Kathryn Ruddy (1)
• Kathryn Sommer (1)
• Kathy Albain (2)
• Kathy Giusti (3)
• Kathy Holliman (2)
• Kathy Miller (1)
• Katie Greenzang (1)
• Katja Wiesel (2)
• Kavita Dharmarajan (1)
• Kavita Mishra (1)
• Kavita Yadav (2)
• Keegan Bales (9)
• Keith Flaherty (2)
• keith mccrae (6)
• Kelly Cotton (1)
• KELLY HEWITT (1)
• Kelly Trevino (1)
• Ken Anderson (1)
• Keneene Lewis (1)
• Kenneth Anderson (10)
• Kenneth Foon (1)
• Kenneth L. Kehl (1)
• Kenneth R. Adler (1)
• Kerin Adelson (2)
• Kerri Winters-Stone (2)
• Kevin B. Knopf (1)
• Kevin Knopf (1)
• Kevin Krull (1)
• Kevin Liou (2)
• Kevin Oeffinger (3)
• KEVIN T. LIOU (2)
• Kevin Weinfurt (1)
• KEYNOTE 014 (1)
• keynote 119 (1)
• keynote trial (2)
• KEYNOTE trials (1)
• KEYNOTE-001 (2)
• KEYNOTE-002 (1)
• KEYNOTE-028 (2)
• KEYNOTE-028 study (1)
• KEYNOTE-042 (1)
• KEYNOTE-045 (1)
• KEYNOTE-045 trial (1)
• keynote-048 (1)
• KEYNOTE-052 (1)
• KEYNOTE-057 (1)
• keynote-062 (1)
• keynote-158 (1)
• keynote-181 (1)
• KEYNOTE-224 (1)
• keynote-426 (2)
• KEYNOTE-427 (2)
• keynote-522 (1)
• Khalid El Bairi (5)
• Khalid El Bairi, Dounia Filali, Nabil Ismaili, Zouhour Bourhaleb, Ali Sbai, Mohamed Marjani, Zineb Benbrahim, Meriem Iraqi Houssaini, Mohamed Mesmoudi (1)
• Khalid Halahleh (1)
• Khalid Rehman (3)
• kidney cancer (54)
• Kidney Cancer (15)
• Kids v Cancer (1)
• Kieron Dunleavy (4)
• killer-cell Ig-like receptor gen (2)
• Kim A. Margolin (1)
• Kim Leary (1)
• Kim Polacek (1)
• Kimberley Lee (1)
• Kimberley T. Lee (1)
• Kimberly Boldig (1)
• Kimmie Ng (3)
• kinase targets (1)
• kindly cancer (3)
• Kings College Hospital (1)
• Kirby Lewis (1)
• Kirsten Boyd Goldberg (14)
• Kishore Dass (1)
• Kishwer Nehal (1)
• KLAUS PUSCHEL (1)
• Koh (1)
• Konrad Stopsack (1)
• Koshy Alexander (1)
• Krankenhaus Nordwest (1)
• KRAS (3)
• KRAS mutations (1)
• Krishna Gundabolu (1)
• Krishnansu Tewari (2)
• Kristen Spencer (1)
• Kristen Whitaker (1)
• kristine trial (1)
• Krzysztof Bujko (2)
• Kwok-Leung Cheung (1)
• Kyle Rove (1)
• L. Elizabeth Budde (2)
• L. Jeffrey Medeiros (19)
• L. Michael Glode (1)
• lack of medical resources (1)
• lack of resources (1)
• Lacouture (1)
• Lancaster General Hospital (1)
• Lanie Brewster Quinn (1)
• laparoscopic (2)
• lapatinib (4)
• Lara Benusis (2)
• large B cell lymphoma (1)
• large cell neuroendocrine lung t (1)
• larotrectinib (1)
• Larry Leichman (1)
• Larry Rosenberg (5)
• Larry Slavens (1)
• Larry Weisenthal (3)
• Larry Wickerham (2)
• laryngeal cancer (1)
• laryngeal preservation (1)
• late effects (3)
• late recurrence (1)
• late side effects (1)
• late stage melanoma (1)
• late toxicity (1)
• late-stage cancer (2)
• late-stage colon cancer (1)
• Latin America (1)
• Latino breast cancer (1)
• LATITUDE trial (4)
• Laura A. Levit (1)
• Laura Esserman (1)
• Laura Greco (1)
• LAURA J. ESSERMAN (1)
• Laura Leavit (1)
• Laura Melton (1)
• Laura Panattoni (1)
• Laura Q.M. Chow (1)
• Laura Rooms (1)
• Laura Veneroni (1)
• Laura Williams Goff (1)
• Lauren Davis (3)
• Lauren Hotaki (1)
• Lauren Wallner (1)
• Laurence H. Baker (4)
• Laurie Gaspar (1)
• Laurie Helen Sehn (1)
• Laurie Lyckholm (1)
• Laurie MacCaskill (1)
• Laurie Sehn (14)
• law (3)
• Lawrence Einhorn (6)
• Lawrence Feldman (1)
• Lawrence Fong (1)
• Lawrence Shulman (5)
• Leah Christl (1)
• Leah Lawrence (11)
• lean body mass (3)
• Lee Jones (1)
• Lee Krug (1)
• Lee Newcomer (4)
• Lee Schwartzberg (11)
• Leena Gandhi (1)
• left side tumor (1)
• left ventricular ejection fratio (1)
• legal issues (2)
• Legislation (2)
• Leiden University Medical Center (1)
• Leiden University Medical Centre (1)
• Leigh Leibel (1)
• leiomyosarcoma (2)
• Leisha Emens (1)
• lenalidomide (22)
• lenaliodmide (1)
• length of treatment (1)
• lenvatinib (4)
• Leo Gordon (3)
• Leonard Berry (1)
• Leonard Gunderson (2)
• Leonard Saltz (5)
• Leonard Zwelling (1)
• Leora Horn (2)
• Lesa Kirkman (1)
• lethal prostate cancer (2)
• letrozole (9)
• leucovorin (2)
• leukemia (42)
• Leukemia (16)
• Levine Cancer Institute (5)
• levothyroxine (1)
• Lewis Foxhall (2)
• Lewis Roberts (1)
• lgbtq (2)
• LGBTQ patients (1)
• LHRH agonists (1)
• Lia Halasz (1)
• Libia Scheller (1)
• Lida Zheng (1)
• Lidia Schapira (2)
• life expectancy (1)
• Life Interrupted (1)
• lifestyle (1)
• lifestyle change (1)
• lifestyle recommendations (1)
• limited-stage disease (1)
• Limo Chen (1)
• Linda Burns (2)
• Linda Carlson (5)
• linda j. burns (6)
• Linda McDonald (1)
• Linda T. Vahdat (1)
• Linda Van Le (1)
• Lindi Campbell (1)
• Linnea Olson (1)
• liposome (1)
• liquid biopsy (3)
• lisa a. carey (3)
• Lisa Arzola (1)
• Lisa Carey (25)
• Lisa Carey MD (1)
• Lisa DeAngelis (1)
• Lisa Diller (3)
• Lisa Marie Ruppert (1)
• Lisa Mendelson (1)
• Lisa Newman (1)
• Lisa Diller (1)
• lisocabtagene maraleucel (1)
• Lital Keinan-Boker (2)
• liver cancer (15)
• liver metastases (6)
• liver SBRT (1)
• liver-directed therapy (1)
• living with cancer (1)
• Liz Janetschek (84)
• Liz Janetschek Pasini (5)
• Liz Pasini (16)
• Liza Marshall (1)
• local control (4)
• local disease (2)
• local recurrence (1)
• local therapy (1)
• localized disease (1)
• localized high risk (1)
• localized prostate cancer (4)
• localized rectal cancer (1)
• locally advanced (2)
• locally advanced breast cancer (3)
• locally advanced cancer (1)
• locally advanced disease (1)
• locally recurrent breast cancer (1)
• locoregional (1)
• locoregional treatment (4)
• locoregionally recurrent breast (1)
• Lodovico Balducci (9)
• Lois Ramondetta (1)
• Lombardi Cancer Center (4)
• lomustine (1)
• London Health Sciences Centre (1)
• long-term ADT (1)
• long-term morbidity (1)
• long-term mortality (1)
• long-term overall survival (1)
• long-term results (1)
• long-term sequelae (1)
• long-term side effects (1)
• long-term survival (2)
• long-term therapy (1)
• Lora Thompson (1)
• Lorenzo Cohen (6)
• Lori Alf (1)
• Lori Goldstein (2)
• Lori J. Wirth (1)
• Lori Pierce (6)
• Lori Wiener (4)
• Lori Wirth (3)
• Loriana Hernandez-Aldama (1)
• Lorraine Egan (1)
• Lorraine McEvoy (1)
• Lorraine Pelosof (2)
• Los Angeles (1)
• loss (1)
• loss of a child (1)
• loss of dignity (1)
• loss of muscle (1)
• LOTUS trial (1)
• Lou Vaickus (1)
• Louis Burt Nabors (1)
• Louis Harrison (1)
• Louis Staudt (1)
• Louise Cooper (1)
• low dose screening (1)
• low HER2-expressing (1)
• low income country (1)
• low resource setting (1)
• low-dose chemotherapy (2)
• low-dose CT (1)
• low-dose CT screening (1)
• Lowell Kleinman (1)
• lower gastrointestinal cancer (1)
• lower mortality (1)
• lower-income patients (1)
• low-fat diet (2)
• low-grade glioma (1)
• low-income (2)
• low-income country (1)
• low-literacy patients (1)
• low-risk (2)
• low-risk prostate cancer (1)
• low-value care (1)
• low-volume prostate cancer (1)
• Loyola University Medical Center (1)
• Lu Daopei Hospital (1)
• Lu-177 dotatate (1)
• Lucas Dean (1)
• Luciano Costa (2)
• Lucy Pickard (1)
• Ludwig Maximilian University of Munich (2)
• Luis A. Diaz (1)
• Luis Alejandro Salicrup (1)
• Luis E. Pino (2)
• LUIS EDUARDO PINO VILLARREAL (1)
• Luis Meza (1)
• Luis Paz-Ares (6)
• Lukas Wartman (1)
• luminal A (1)
• luminal type breast cancer (1)
• lumpectomy (3)
• lung cancer (121)
• Lung Cancer (43)
• Lung Cancer Alliance (1)
• lung cancer risk (1)
• lung cancer screening (3)
• lung cancer staging (1)
• lung cancer workup (1)
• lung dose (1)
• lung toxicity (1)
• LungenClinic (3)
• LUNGMAP (1)
• lupus (1)
• lurbinectedin (3)
• Lurie Comprehensive Cancer Cente (1)
• luspatercept (1)
• LUX-Lung 7 Trial (2)
• LUX-Lung 8 (1)
• LY2606368 (1)
• LYDIA CAIRNCROSS (1)
• LyMa trial (2)
• lymph node (2)
• lymph node assessment (1)
• lymph node dissection (2)
• lymph node surgery (1)
• lymph nodes (1)
• lymphadenectomy (2)
• lymphedema (1)
• lymphoblastic leukemia (1)
• lymphocytes (1)
• lymphocytic infiltration (1)
• lymphoid malignancies (2)
• lymphoma (72)
• Lymphoma (19)
• lymphoma survivors (1)
• lymphomas (1)
• lymphoplasmacytic lymphoma (1)
• lynch syndrome (1)
• Lynda Balneaves (1)
• Lynn Cancer Institute (1)
• Lynn Sage Comprehensive Breast C (1)
• LYNN SCHUCHTER (1)
• Lynn Volk (1)
• Lynne Lederman (1)
• Lysa Remarc Study (1)
• Lysa Remarc trial (1)
• Lysa study (2)
• M D Anderson (1)
• M. Catherine Pietanza (2)
• M. Gregg Bloche (1)
• M. Shaalan Beg (1)
• M. Steven Piver (2)
• MA20 (1)
• Mace Rothenberg (1)
• Mafalda Von Alvensleben (1)
• magnetic resonance imaging (2)
• Maha Hussain (5)
• Mahmoud Al-Hawary (1)
• MAIA trial (1)
• maintenance (1)
• maintenance BCG therapy (1)
• maintenance monotherapy (1)
• maintenance therapy (5)
• Mairéad Geraldine McNamara (1)
• Maki Tania (1)
• male patients (1)
• Malgorzata Mikulska (1)
• mammography (2)
• mammography guidelines (1)
• management of lung cancer (1)
• Managing Editor (1)
• managing toxicities (1)
• Manali Patel (2)
• Mani Menon (1)
• Manish Shah (1)
• Manisha H. Shah (1)
• Manisha Shah (2)
• Mansoor Mirza (1)
• Mansoor Raza Mirza (2)
• mantle cell (1)
• mantle cell lymphoma (11)
• Manuel Hidalgo (1)
• Manuj Agarwal (3)
• Marc Lawler (1)
• Marc R. Theoret (1)
• Marc Theoret (1)
• Marc Ychou (1)
• Marcel Rozencweig (1)
• Marcel Verheij (1)
• Marci Greenberg Cox (1)
• Marcus Randall (1)
• Margaret A. Tempero (1)
• Margaret Callahan (1)
• Margaret Hamburg (1)
• Margaret Kasner (1)
• Margaret O’Donnell (1)
• Margaret O'Donnell (1)
• Margaret Tempero (3)
• Margaret von Mehren (2)
• Margaret Werts (1)
• margetuximab (2)
• marginal zone lymphoma (1)
• Margot Fromer (2)
• Margot J. Fromer (55)
• Maria Cabanillas (1)
• Maria Clemence Schwaederle (1)
• Maria Sklodowska Curie Cancer Ce (1)
• Maria Werner-Wasik (2)
• Mariame Chraibi (1)
• Mariana Figueiro (1)
• Marie Bleakley (1)
• Marie Elaine Price-Lockridge (1)
• Marie Krejci (1)
• Marie Sabo Recine (6)
• Marie-Andree Forget (1)
• Mario E. Lacouture (6)
• Mario Sznol (4)
• marital status (1)
• Marjory Charlot (1)
• Mark Helvie (1)
• Mark Lazenby (2)
• Mark Lewis (1)
• Mark McCamish (1)
• Mark R. Gilbert (1)
• Mark Ratain (3)
• Mark Robson (2)
• Mark Roschewski (2)
• Mark Smith (1)
• Mark Talamonti (1)
• Mark Trombetta (1)
• marker decline (1)
• Marleen Kok (1)
• Marlise R. Luskin (1)
• Marseille Cancer Center (2)
• Marsha Axler (1)
• Marsha Edwards (1)
• Martee Hensley (1)
• Martha Donoghue (1)
• Martha Tracy (1)
• Martin Edelman (1)
• Martin Reck (2)
• Martin Schrappe (2)
• Martin Schuler (2)
• Martin Tallman (3)
• Martin Van Den Vent (1)
• Martine Extermann (1)
• Martine Frouws (2)
• Martine Piccart (1)
• Martine Piccart-Gebhart (5)
• Marvin Stone (1)
• Marwan Fakih (1)
• MARY ALMA WELCH (1)
• Mary B. Daly (1)
• Mary Bridge Children's Hospital (1)
• Mary Evelyn Burman (1)
• Mary Gospodarowicz (6)
• Mary Longhini (1)
• Mary Lou Smith (2)
• Mary McCabe (6)
• MARY MULCAHY (1)
• Mary Pasquinelli (1)
• Mary Vargo (1)
• Masanori Terashima (1)
• Mass Gen (2)
• Massachusetts General (7)
• Massachusetts General Hospital (14)
• massage (1)
• Massimo Cristofanilli (2)
• mastectomy (5)
• MATCH trial (1)
• Matt Ellefson (1)
• Matt Kalaycio (1)
• Matt Lunning (1)
• Matteo Lambertini (3)
• Matteo Silva (1)
• Matthew Ellis (6)
• Matthew Galsky (1)
• Matthew Goetz (1)
• Matthew Hellmann (1)
• matthew j. ellis (1)
• Matthew J. Resnick (1)
• Matthew Loscalzo (2)
• matthew lunning (5)
• Matthew Smith (2)
• Matthew Stenger (4217)
• MATTHEW ZIBELMAN (1)
• Matti Aapro (7)
• Maura Dickler (3)
• Maura Gillian (1)
• Maura Gillison (2)
• Maura Massimino (1)
• Maureen Markham (1)
• Maureen Roberts (1)
• Maurie Markman (2)
• MAVERICC study (2)
• Maximilian Diehn (1)
• Maxwell Krem (1)
• Mayo Clinc Cancer Center (3)
• Mayo Clinic (35)
• Mazie Tsang (1)
• MBA (1)
• MBBCh (1)
• mbc (1)
• MBChB (1)
• mcc (1)
• McGill (3)
• mcguire lecture (1)
• MCL (6)
• McMaster University (2)
• mcrc (1)
• mcrpc (1)
• MD (12)
• MD Abdul Wadud Khan (1)
• MD Anderson (23)
• MD Anderson Cancer Center (14)
• MD; Lola Fashoyin-Aje (1)
• MD; Marc R. Theoret (1)
• MD; Martha B. Donoghue (1)
• MD; Paul G. Kluetz (1)
• MD; Richard Pazdur (1)
• MDS (5)
• meaning centered psychotherapy (4)
• meaning centered therapy (1)
• MEC inhibitor (1)
• Medalist trial (1)
• medicaid (1)
• Medicaid expansion (1)
• medical burden (1)
• Medical College of Wisconsin (1)
• medical complications (2)
• medical fellows (1)
• medical fellowship (1)
• medical oncologist (1)
• medical oncology (1)
• Medical Oncology Rosebank (1)
• medical reporting (1)
• Medical University of Vienna (2)
• Medical University Vienna – Ge (1)
• medicare (1)
• medication adherence (1)
• meditation (1)
• medullary (1)
• Meena Moran (1)
• Meena S. Moran (2)
• Meg Barbor (144)
• Meg O'Brien (1)
• Megan Caram (1)
• Megan Daly (1)
• Mehment Sitki Copur (1)
• Melanie E. Royce (1)
• Melanie Royce (2)
• Melanie Seal (1)
• melanoma (34)
• Melanoma (2)
• Melanoma Institute Australia (2)
• melanoma survivor (1)
• melflufen (1)
• Melinda Bachini (1)
• Melinda Telli (1)
• Melissa Crouse (1)
• Melissa Fryman (1)
• Melissa Johnson (1)
• Melissa McShane (1)
• melphalan (1)
• Memorial Sloan Kettering (78)
• Memorial Sloan Kettering Cancer (2)
• Memorial Sloan Kettering Cancer Center (26)
• men (1)
• meningioma (1)
• menopausal symptoms (1)
• menopause (2)
• men's health (1)
• mental health (2)
• mental health status (1)
• mental illness (1)
• mentee (1)
• mentor (2)
• mentorship (3)
• Meredith Baker (1)
• merkel cell carcinoma (3)
• Merrick I. Ross (1)
• mesothelioma (3)
• MET amplification (1)
• MET mutation (2)
• metabolic syndrome (3)
• metastasectomy (2)
• metastases (1)
• metastasis (3)
• metastasis free survival (1)
• metastasis score (1)
• metastatic (20)
• metastatic bladder cancer (2)
• metastatic breast cancer (20)
• metastatic burden (1)
• metastatic cancer (9)
• metastatic cancer care (1)
• metastatic cancer pain (1)
• metastatic castration-resistant prostate cancer (1)
• metastatic colon cancer (1)
• metastatic colorectal cancer (9)
• metastatic disease (3)
• metastatic head and neck cancer (1)
• metastatic hormone-naive prostat (1)
• metastatic lung cancer (3)
• metastatic melanoma (4)
• metastatic nsclc (1)
• metastatic prostate cancer (3)
• metastatic renal cell carcinoma (1)
• metastatic solid cancer (2)
• metastatic solid tumors (1)
• metastatic spinal cord compressi (1)
• metastatic tumors (1)
• metastatic urothelial cancer (1)
• metastatic urothelial carcinoma (1)
• METEOR trial (4)
• metformin (2)
• methotrexate (1)
• methylation (1)
• mFFOX (1)
• mFOLFIRINOX (2)
• mfolfox6 (2)
• mFOLFOX6-bevacizumab (2)
• Mhairi Copland (1)
• mibc (2)
• Michael Alvarado (1)
• Michael Becker (3)
• Michael Bookman (1)
• Michael Cecchini (2)
• Michael Davies (1)
• Michael E. Williams (1)
• Michael Feinstein (1)
• Michael Fisch (1)
• Michael Gnant (2)
• Michael Green (1)
• Michael Hoerger (1)
• Michael Irwin (1)
• Michael J. Hall (1)
• Michael J. Overman (2)
• Michael K. Gibson (1)
• Michael Kraut (1)
• Michael LeFevre (1)
• Michael Link (1)
• Michael Mauro (1)
• Michael Overman (1)
• Michael Perrotta (1)
• Michael Pfreundschuh (2)
• Michael Postow (3)
• Michael Sabel (2)
• Michael Schweizer (1)
• Michael Stubblefield (1)
• Michael T. Schweizer (1)
• Michael Thompson (1)
• Michael Van Scoy-Mosher (1)
• Michael Wang (1)
• Michel Ducreux (2)
• Michela Casanova (1)
• Michele Beau-Faller (1)
• Michele Cavo (2)
• Michele Schuman (1)
• Michelle Dalton (1)
• Michelle LeBeau (1)
• Michelle Lynn Mierzwa (1)
• microbes (1)
• microbiota (1)
• microsatellite instability (4)
• microsatellite instability high (1)
• microsatellite instability-high (1)
• microsatellite stable (1)
• middle income country (1)
• middle-income country (1)
• midgut (1)
• midgut tumors (1)
• midostaurin (1)
• Miguel-Angel Perales (1)
• Mike Armstrong (1)
• Mikkael A. Sekeres (2)
• Mikkael Sekeres (3)
• MIKRAM KHARMACH (1)
• Milan Anadkat (2)
• Milena Sant (2)
• Milind Javle (1)
• Mindy Greenstein (2)
• Mindy Tanzola (10)
• Mingzhao Xing (1)
• minimal residual disease (4)
• minimally invasive (3)
• minimally invasive surgery (1)
• minority (1)
• minority patients (1)
• Mirat Shah (1)
• Miri Ziv (2)
• Miriam A. Knoll (1)
• mirvetuximab soravtansine (1)
• Mischa P. M. Nagel (1)
• misdiagnosis (1)
• mismatch repair (2)
• mismatch repair deficiency (1)
• mismatch repair-deficient (1)
• mismatched repair genes (1)
• missed appointments (1)
• MIT (1)
• Mitchell Cairo (2)
• Mitchell Chan (1)
• Mitchell Dowsett (2)
• Mitchell Garrison (1)
• Mitchell Smith (1)
• Mithat Gonen (1)
• mitomycin (1)
• mitoxantrone (1)
• MMed (1)
• mmr (1)
• mmr deficient (1)
• MOAWIA MOHAMMED ALI ELHASSAN (1)
• mobile app (1)
• mobility (1)
• modality therapy (1)
• moderate-penetrance mutations (1)
• Moffitt Cancer Care (1)
• Moffitt Cancer Center (6)
• MOHAMED ALORABI (1)
• Mohammad Abu Zaid (1)
• Mohammad K. Khan (2)
• Mohammed Shimi (1)
• molecular (1)
• molecular analyses (1)
• molecular analysis (3)
• molecular biology (1)
• molecular predictor (1)
• molecular profiling (1)
• molecular screening (2)
• molecular subtypes (2)
• molecular testing (2)
• Molly MacDonald (1)
• momelotinib (1)
• monaleesa-7 (1)
• MONARCH 2 (1)
• Monash University (2)
• Monica Bertagnolli (2)
• Monica Morrow (2)
• Monica Terenziani (1)
• Monika Krzyzanowska (1)
• Monique Hartley-Brown (1)
• monoclonal antibodies (3)
• monoclonal antibody (4)
• monocytes (1)
• monotherapy (5)
• Montefiore Medical Center (2)
• mood (1)
• Moores Cancer Center (3)
• MOR208 (1)
• morbidity (1)
• Morgan Romero (1)
• mortality (3)
• mortality rate (1)
• Mothaffar Rimawi (1)
• motolimod (1)
• Mounika Addula (1)
• Mount Sinai (2)
• Mount Vernon Cancer Centre (1)
• moxetumomab pasudotox (1)
• MPH (1)
• MPH; Jeff Summers (1)
• mrcpc (1)
• mrd (2)
• MRI (3)
• Mrinal Patnaik (2)
• msi (1)
• MSI mutation (1)
• msi-h (1)
• MSKCC (3)
• MSLT2 trial (1)
• mss (1)
• Mt Sinai (1)
• mTOR (1)
• mTOR inhibitor (1)
• mucositis (2)
• Muhamad Alhaj Moustafa (1)
• Muhamed Baljevic (1)
• Muhammad Rafiqul Islam (2)
• mulitcatheter brachytherapy (1)
• multi fraction radiotherapy (1)
• multicatheter interstitial brach (1)
• multidisciplinary (3)
• multidisciplinary care (1)
• multidisciplinary health-care (1)
• multikinase inhibitor (1)
• multimodality (1)
• multi-parametric (1)
• multiple myeloma (55)
• Multiple Myeloma (18)
• MURANO (1)
• MURANO trial (1)
• MURIEL CUNNINGHAM (1)
• Murray Brennan (5)
• muscle (1)
• muscle invasive (1)
• muscle loss (1)
• muscle mass (1)
• muscle strength (1)
• muscle-invasive (1)
• muscle-invasive bladder cancer (5)
• musculoskeletal symptom (1)
• mutated pathways (1)
• mutation burden (2)
• mutations (2)
• MYC (1)
• MYC translocation (1)
• mycophenolate mofetil (1)
• myeloablative AHCT (1)
• Myelodysplastic Syndomes (3)
• myelodysplastic syndrome (9)
• myelofibrosis (6)
• myeloid growth factors (1)
• myeloid neoplasms (1)
• myeloma (8)
• myeloma clones (1)
• myeloproliferative neoplasms (2)
• Myl-1401O. (1)
• MyPathway trial (1)
• N. Lynn Henry (1)
• Nabiel Mir (1)
• nab-paclitaxel (9)
• NADA SULIMAN HAJ MUKHTAR (1)
• Nadeem Abu-Rustum (1)
• Nadia Harbeck (1)
• Nadine Tung (1)
• Nafisa Abdelhafiez (1)
• Nagashree Seetharamu (2)
• NAGI EL SAGHIR (1)
• NAGI S. EL SAGHIR (1)
• Nagi S. El-Saghir (2)
• naive T cell depletion (1)
• Naiyer Rizvi (2)
• nala trial (2)
• Namrata Vijayvergia (1)
• Nancy Davidson (4)
• Nancy Lin (3)
• Nantes University Hospital (2)
• Narjust Duma (1)
• Narjust Florez (Duma) (1)
• Narmin Talibova (1)
• Natasha Leighl (1)
• Natasha Stout (1)
• Nathalie McKenzie (2)
• Nathan Fowler (2)
• Nathan Hale Fowler (1)
• Nathan Pennell (1)
• National Cancer Center Bejing (1)
• National Cancer Center Hospital (1)
• National Cancer Data Base (1)
• National Cancer Database (2)
• National Cancer Institute (14)
• National Cancer Institute of Mil (1)
• National Coalition for Cancer Research (1)
• National Jewish Health (1)
• national policy (1)
• National Taiwan University (1)
• natural killer cells (2)
• nausea (6)
• Naveen Pemmaraju (1)
• Navneet Majhail (2)
• Nawfel Mellas (1)
• NCCN (64)
• nccn 2020 (5)
• NCCN 22nd Annual Conference (4)
• nccn annual conference (6)
• NCCN guidelines (11)
• NCCN Hematologic Malignancies (19)
• nccn, nccn annual conference, 4R model, pathways (1)
• NCCTG N063H (1)
• NCI (6)
• NCI cancer center (2)
• NCTN (1)
• Neal Chawla (1)
• Neal Meropol (3)
• Neal Ready (1)
• Neal Shore (1)
• Nebraska Cancer Specialists (1)
• Nebraska Medicine (1)
• necitumumab (2)
• neck dissection (1)
• needle biopsy (1)
• Neel U. Sukhatme (1)
• Neeraj Agarwal (2)
• Neil Canavan (4)
• Neil Iyengar (2)
• Neil Vasan (1)
• NEJ026 trial (1)
• nelipepimut-s (1)
• Nelli Benjanyan (1)
• Nelson Peralta (1)
• Nengliang Yao (1)
• neoadjuvant (3)
• neoadjuvant chemotherapy (9)
• neoadjuvant ipilimumab (2)
• neoadjuvant radiation (1)
• neoadjuvant therapy (8)
• neoadjuvant treatment (6)
• neoantigen (1)
• neoantigen vaccine (1)
• neoMONARCH (1)
• neoMONARCH trial (1)
• NEOSCOPE trial (1)
• NeoSphere trial (1)
• neotrip (1)
• nephrectomy (8)
• neratinib (3)
• Netherlands Cancer Institute (5)
• Netherlands Comprehensive Cancer (1)
• NETs (1)
• NETTER-1 (1)
• NETTER-1 trial (1)
• neuroblastoma (5)
• neurocognitive (1)
• neuroendocrine (1)
• neuroendocrine disease (1)
• neuroendocrine tumors (7)
• neurologic side effects (1)
• neurologic toxicity (1)
• neuropathic pain (2)
• neuropathy (5)
• neurotoxicity (4)
• neutropenia (3)
• never smoker (1)
• never smokers (2)
• new mexico (1)
• New York University (1)
• newly diagnosed cancer patients (1)
• NewYork-Presbyterian (1)
• next generation sequencing (1)
• next therapy (1)
• next-generation sequencing (3)
• nf1 (1)
• NGS (6)
• NHL (6)
• Nicholas J. Vogelzang (1)
• Nicholas James (5)
• Nicholas Simon (1)
• Nicholas Turner (5)
• Nicolaus Kröger (1)
• Nicole Kuderer (1)
• Nicole Mittmann (1)
• Nicole Shonka (1)
• Nicolò Matteo Luca Battisti (1)
• nicotinamide (2)
• Nienke A. de Glas (1)
• Nikhil Wagle (2)
• nilotinib (2)
• Nina Rosa Neuendorff (1)
• Nina Shah (1)
• nintedanib (1)
• niraparib (8)
• Nirupa Raghunathan (5)
• Nita Ahuja (1)
• Nithya Krishnan (2)
• Nitin Jain (1)
• Nitin Mehrotra (1)
• nivolumab (49)
• nivolumab dosing (1)
• nivolumab monotherapy (3)
• NIVOREN GETUG-AFU 26 (1)
• NIZAR TANNIR (1)
• nk cells (1)
• NK1 inhibitor (1)
• nodal irradiation (1)
• nodal radiation (1)
• nodal response (1)
• node negative (1)
• node-negative (5)
• node-positive (2)
• node-positive disease (1)
• nodules (2)
• Noelle LoConte (1)
• non-bulky (1)
• non-clear cell renal cancer (2)
• noncolorectal GI cancers (1)
• non-favorable AML (1)
• Non-Hodgkin lymphoma (12)
• nonmelanoma skin cancer (2)
• non-melanoma skin care (2)
• nonmetastatic (2)
• non-muscle invasive (1)
• non-muscle-invasive bladder canc (1)
• nonpharmacological techniques (1)
• nonseminoma (1)
• non-small cell lung cancer (33)
• non–small cell lung cancer (4)
• nonsmoking-associated (1)
• non-specific symptoms (1)
• nonsquamous (3)
• nonverbal (1)
• Nora Janjan (2)
• Nordwest Hospital (2)
• NORMAN J. LACAYO (1)
• Norman Sharpless (3)
• Norman Wolmark (2)
• Norris Cotton Cancer Center (1)
• North Shore LIJ (1)
• NorthShore University Health (1)
• Northwestern (1)
• Northwestern University (5)
• novel agents (1)
• novel combination (1)
• novel drug targets (1)
• novel pathways (1)
• novel-novel (1)
• n-Pacific Lymphoma 2016 (1)
• NRG Oncology (6)
• NRG Oncology/NSABP B-42 (2)
• NRG Oncology/NSABP B-42 trial (1)
• NRG Oncology/NSABP B-52 trial (1)
• nrg/nsabp (1)
• NRG/RTOG 0712 (1)
• NSABB (1)
• NSABP (2)
• NSABP 35 (1)
• NSABP B20 (1)
• NSABP B-35 (1)
• NSABP B-36 (1)
• NSABP B-47 trial (1)
• NSABP clinical trials (1)
• NSCLC (69)
• NSGO-PALEO / ENGOT-EN3 trial (1)
• nursing homes coronavirus (1)
• nut consumption (1)
• NYU (2)
• NYU Langone (2)
• NYU Perlmutter Cancer Center (2)
• OAK trial (2)
• obamacare (1)
• obesity (5)
• obinutuzumab (11)
• objective response (1)
• observation (3)
• OCE members (1)
• Octreotate (1)
• Octreotide (1)
• Ogidiagba Louis Efe (1)
• ogliometastatic (1)
• ogliometastatic disease (1)
• Ohio State University (3)
• OhioHealth (2)
• Ohiohealth Kobacker House (1)
• Ola Landgren (3)
• olanzapine (3)
• olaparib (12)
• olaratumab (1)
• older cancer survivor (1)
• older patients (11)
• oligometastatic (5)
• Oliver Sartor (4)
• Olivier Casasnovas (4)
• Olivier Chinot (1)
• Olivier Tredan (1)
• Ollie Minton (1)
• Olufunmilayo I. Olopade (2)
• OlympiAD trial (1)
• omega-3 fatty acid (1)
• Omid Hamid (2)
• omitting surgery (1)
• oncologic surgery (1)
• oncologist partnering (1)
• oncologist perception (1)
• oncology (53)
• oncology care (1)
• Oncology Care Model (2)
• oncology in India (1)
• oncology in South America (1)
• oncology in the Middle East (1)
• oncology provider (1)
• OncologyGo (4)
• oncopolicy (1)
• Oncotype DX (5)
• online curriculum (1)
• online patient information (1)
• online tumor board (1)
• oocyte (1)
• OP-106 Horizon (1)
• OpACIN trial (2)
• open (1)
• open resection (1)
• open transthoracic (1)
• operable cancer (1)
• opiates (1)
• opinion (4)
• opiod prescribing (1)
• opiod risk (1)
• opioid (3)
• opioid abuse (1)
• opioid access (2)
• opioid addiction (1)
• opioid epidemic (1)
• opioid reduction (1)
• opioid use (1)
• opioid use disorder (1)
• opioid-associated death (1)
• opioids (6)
• opioids and cancer pain (1)
• opportunity cost (1)
• optimal sequencing (1)
• OPTIMAL>60 study (1)
• oral anticoagulants (2)
• oral azacitidine (1)
• oral cancer (1)
• oral cavity (1)
• oral chemotherapy (1)
• oral HPV infection (1)
• oral mucositis (1)
• oral paclitaxel (1)
• oral regimen (1)
• Oregon (1)
• Oregon Health & Science (1)
• Oregon Health & Science Universi (1)
• organ preservation (1)
• oriole trial (1)
• oropharyngeal (1)
• oropharyngeal cancer (4)
• Oscar B. Goodman (1)
• OSCAR GUEVARA (1)
• osimertinib (2)
• osteoradionecrosis (1)
• OSUCCC (1)
• other-cause mortality (1)
• Otis Brawley (1)
• Ottawa Hospital Cancer Centre (1)
• Otterson (1)
• OUISSAM AL JARROUDI (1)
• outcome (1)
• outcomes (2)
• outcomes analysis (1)
• outcomes research (1)
• out-of-pocket costs (1)
• outpatient care (1)
• outpatient treatment (1)
• ovarian cancer (25)
• ovarian failure (1)
• ovarian function (2)
• ovarian function suppression (2)
• ovarian insufficiency (1)
• ovarian suppression (7)
• overall survival (22)
• overall survival analysis (2)
• overtreatment (2)
• OVHIPEC trial (1)
• Owen N. Witte (1)
• Owen O'Connor (1)
• oxaliplatin (13)
• Oxford University (1)
• oxybutynin (1)
• oxygen (1)
• p16 (1)
• PAC (1)
• pace-b trial (1)
• PACIFIC trial (3)
• paclitaxel (19)
• pacritinib (1)
• PADMA trial (1)
• Padmanee Sharma (1)
• pain (2)
• pain assessment (2)
• pain flare (1)
• pain management (4)
• Pain Management (2)
• pain relief (2)
• pain score (1)
• painful bone metastases (1)
• painkillers (1)
• PAKT trial (1)
• palb2 (1)
• palbociclib (11)
• PALLAS trial (1)
• palliative (1)
• palliative care (33)
• Palliative Care (2)
• palliative care clinicians (2)
• palliative care in cancer (1)
• palliative care integration (1)
• palliative chemotherapy (1)
• PALOMA (1)
• PALOMA 3 (1)
• PALOMA-1/TRIO 18 (1)
• PALOMA3 (2)
• palpable stage 3 melanoma (2)
• Pam Kohl (1)
• Pamela Kunz (1)
• PAMELA trial (2)
• Pan Pacific Lymphoma (16)
• PANACEA (1)
• pancreatic cancer (25)
• Pancreatic Cancer (11)
• pancreatic carcinoma (1)
• pancreatic ductal adenocarcinoma (1)
• pancreatic ductal carcinoma (1)
• pancreatic resection (1)
• pancreatic tumors (1)
• pandemic (1)
• panitumumab (1)
• PANKAJ JANI (1)
• panobinostat (1)
• Pan-Pacific Lymphoma 2016 (17)
• Paola Gaggiotti (1)
• paola-1 (1)
• paola-1/engot-ov25 trial (1)
• Paoli Palmettes Institute (2)
• Paolo Ascierto (2)
• Paolo Strati (1)
• papillary RCC (1)
• papillary renal cell carcinoma (2)
• Parameswaran Hari (3)
• parents (1)
• Parkland Health System (1)
• Parminder Singh (1)
• PARP inhibitor (9)
• PARP inhibitors (4)
• partial breast radiation (2)
• partial breast re-irradiation (1)
• partial-breast irradiation (1)
• partnership (1)
• Parvez Dara (4)
• Pasi Jänne (2)
• Pasi S. Jänne (2)
• passenger mutations (1)
• pathologic (1)
• pathologic complete response (4)
• pathology (1)
• pathway (1)
• pathways (5)
• Pati Schembari (1)
• patient advocacy (1)
• patient advocate (3)
• patient burden (1)
• patient care (1)
• patient communication (1)
• patient costs (1)
• patient counseling (1)
• patient decision-making (1)
• patient distress (1)
• patient education (1)
• patient engagement (1)
• patient experience (1)
• patient features (1)
• patient feedback (1)
• patient information (1)
• patient navigation (2)
• patient navigator (1)
• patient outcomes (3)
• patient perception (1)
• patient perspective (1)
• patient preference (2)
• patient reported outcomes (3)
• patient reporting (1)
• patient safety (1)
• patient satisfaction (1)
• patient selection (2)
• patient-centered cancer care (1)
• patient-centered care (5)
• patient-reported data (1)
• patient-reported outcome (2)
• patient-reported outcomes (7)
• patient-reported surveys (1)
• patient-reported symptoms (1)
• patients (1)
• Patricia Eifel (1)
• Patricia Ganz (9)
• Patricia Hurley (1)
• Patricia J. Goldsmith (1)
• PATRICIA trial (1)
• Patrick Beauregard (2)
• Patrick Boland (1)
• Patrick Eck (1)
• Patrick Forde (1)
• Patrick M. Lynch (1)
• Patrick Schoffski (1)
• Patrick Schöffski (1)
• patterns of care (1)
• Paul A. Bunn Jr (3)
• Paul Bunn (4)
• Paul Chapman (1)
• Paul Goss (1)
• Paul Jacobsen (2)
• Paul Kalanithi (2)
• Paul Kluetz (2)
• Paul M. Cinciripini (1)
• Paul Nguyen (7)
• Paul O'Gorman Leukaemia Research (1)
• Paul Richardson (4)
• Paul Weiden (1)
• Pauline Funchain (1)
• PAVLOS MSAOUEL (1)
• payer (1)
• payer perspective (1)
• Paz-Ares (1)
• pazopanib (5)
• pbi (1)
• PCORI (1)
• PCP (1)
• PCR (4)
• PD-1 (3)
• pd-1 blockade (4)
• PD-1 combination therapy (1)
• PD-1 inhibitors (2)
• PD-1 monotherapy (1)
• PD-1 therapy (1)
• PD1-blockers (1)
• PDAC (2)
• PDC (1)
• PDL1 (3)
• PD-L1 (16)
• PD-L1 immunotherapy (1)
• PD-L1 inhibition (1)
• PD-L1 positive (1)
• PDL1 staining (1)
• PDL1-blockers (1)
• pd-l1-negative (1)
• PD-L1-positive (2)
• PDL2 expression (1)
• pearl trial (1)
• pediatric (2)
• pediatric cancer (3)
• pediatric chemotherapy (1)
• pediatric leukemia (2)
• pediatric oncology (3)
• Pedram Razavi (1)
• pegilodecakin (1)
• pegph20 (1)
• pelvic lymph node (1)
• pelvic radiation (1)
• pembrolizumab (48)
• pemetrexate (1)
• pemetrexed (3)
• penile cancer (2)
• Pennsylvania Hematology Oncology (1)
• Pennsylvania Hospital (2)
• peptide-paclitaxel conjugate (1)
• peptides (1)
• Pere Gascón (1)
• performance measures (1)
• perimenopausal (1)
• periodontal disease (1)
• perioperative (1)
• perioperative chemotherapy (1)
• peripheral blood stem cell (1)
• peripheral blood stem cells (1)
• peripheral neuropathy (1)
• peripheral T cell lymphoma (3)
• peripheral T-cell lymphoma (2)
• peritoneal cancer (1)
• peritoneal carcinoma (2)
• peritoneal carcinomatosis (2)
• peritoneal metastases (1)
• Persephone trial (2)
• PERSIST Trial (2)
• personal doses (1)
• personalized cancer care (1)
• personalized medicine (6)
• personalized treatment (2)
• personalized vaccine (1)
• pertuzumab (5)
• PET (3)
• PET CT (1)
• PET scan (7)
• Peter Bach (3)
• Peter Clark (2)
• Peter Greenberg (1)
• Peter Hoskin (1)
• Peter Johnstone (1)
• Peter L.J. Naredi (1)
• Peter MacCallum Cancer Centre (4)
• Peter MacCallum Centre (3)
• Peter Naredi (1)
• Peter O'Donnell (1)
• Peter Paul Yu (4)
• Peter Shields (2)
• Peter Watson (1)
• Peter Yu (1)
• Peter Wiernik (1)
• Petros Grivas (1)
• pfs (6)
• Ph+ ALL (1)
• phaedra trial (1)
• PHARE trial (1)
• pharmacogenomic (1)
• phase 1 trials (1)
• phase I clinical trial (1)
• phase I trial (1)
• PhD (2)
• PhD; and Olexiy Kovalyov (1)
• PhD; Iryna Kriachok (1)
• PhD; Ivan Smolanka (1)
• PhD; Jennifer J. Gao (1)
• PhD; LAWRENCE N. SHULMAN (1)
• PhD; Nataliia Dovganych (1)
• PHIL FALKOWITZ (1)
• philadelphia chromosome (1)
• Philip A. Thompson (2)
• Philip Bonomi (5)
• Philip Champion (1)
• Philip Kantoff (2)
• Philip Salem (1)
• Philip Stella (1)
• Philippe Rochigneux (2)
• Philippe Spiess (1)
• Phillip Gray (1)
• Ph-negative (1)
• photon therapy (1)
• physical activity (2)
• physical experience (1)
• physical function (1)
• physical therapy (1)
• physician burnout (1)
• physician’s choice (1)
• physician-assisted death (1)
• physician-assisted suicide (1)
• physician-led (1)
• Physicians' Health Study (1)
• PI3K (2)
• PI3K inhibition (1)
• PI3K inhibitor (2)
• pictilisib (2)
• PIK3CA (2)
• Piyush Agarwal (1)
• placebo effect (1)
• PlanB trial (1)
• plasma (1)
• plasma cell leukemia (1)
• plasma cell-free DNA (1)
• plasma DNA (1)
• plasmacytoma (1)
• plasmamatch (1)
• platelet transfusion (1)
• platinum (1)
• platinum chemotherapy (7)
• platinum combination chemotherap (1)
• platinum-based (1)
• platinum-based chemo (1)
• platinum-based chemotherapy (2)
• platinum-ineligible (2)
• platinum-resistant (2)
• platinum-sensitive (4)
• playwright (1)
• PLD-1 (1)
• plenary (1)
• pneumonitis (2)
• polatuzumab vedotin (2)
• policy (3)
• policy issues (2)
• politics (2)
• polo trial (1)
• polybromo (1)
• polycythemia vera (1)
• polygenic risk scores (1)
• polymerase epsilon mutation (1)
• pomalidomide (2)
• ponatinib (2)
• Ponnandai S. Somasundar (1)
• pooled data analysis (1)
• poor prognosis (2)
• poor response (1)
• poor-prognosis (2)
• poor-prognosis tumors (1)
• poor-risk (1)
• POSH study (1)
• positive lymph nodes (2)
• positron emission tomography (1)
• positron emission topography (2)
• postmenopausal (10)
• postmenopausal breast cancer (4)
• postmenopausal patients (1)
• postmenopausal women (1)
• postoperative radiation (2)
• postplatinum (1)
• post-remission (1)
• postsurgery (1)
• postsurgical (1)
• postsurgical syndromes (1)
• post-treatment care (1)
• post-treatment services (1)
• Prasad Adusumilli (1)
• Prashant Kapoor (1)
• precision medicine (7)
• precision oncology (1)
• predict survival (1)
• predictive biomarker (2)
• predictive biomarkers (1)
• predictive factors (1)
• prednisone (9)
• Preety Narayan (1)
• pregnancy (5)
• premenopausal (6)
• pre-menopausal (1)
• premenopausal breast cancer (1)
• premenopausal patients (1)
• premenopausal women (1)
• PREOPANC-1 (1)
• preoperative (1)
• preoperative chemotherapy (1)
• preoperative exercise (1)
• preoperative radiotherapy (1)
• prescribing opioids (1)
• presurgery (2)
• pretreated (3)
• pretreated colorectal cancer (1)
• prevention (1)
• previously treated lung cancer (1)
• prexasertib (1)
• PRIMA trial (1)
• prima/engot-ov26/gog-3012 (2)
• primary care (2)
• primary care physician (1)
• primary care provider (2)
• primary glioma (1)
• primary treatment (1)
• primary tumor location (1)
• primary tumors (1)
• Primo Lara (1)
• Princess Dina Mired (1)
• Princess Margaret Cancer Centre (4)
• Princess Margaret Hospital (5)
• prior authorization (1)
• Priscilla Brastianos (3)
• procarbazine (1)
• PRODIGE 24 (1)
• PRODIGE 7 (1)
• PRODIGY 12-ACCORD 18 (3)
• Prof. Kouhen Fadila (1)
• ProfilER study (1)
• profound trial (1)
• progestin (1)
• prognosis (2)
• prognostic (2)
• prognostic awareness (1)
• prognostic biomarker (2)
• prognostic information (1)
• prognostic model (1)
• prognostic models (1)
• prognostic stage (1)
• prognostic uncertainty (1)
• prognostication (1)
• programmed cell death ligand 1 (1)
• programmed cell death protein 1 (1)
• progress (2)
• progression-free survival (9)
• progressive cancer (1)
• project facilitate (1)
• prolonged grief disorder (1)
• PROMIS (1)
• PROMIS group (1)
• PROMISE trial (1)
• proof of concept (1)
• pros (3)
• pros and cons (1)
• PROSPER trial (2)
• prostate (1)
• prostate bed (1)
• prostate cancer (98)
• Prostate Cancer (26)
• prostate cancer guidelines (1)
• prostate cancer subclass (1)
• prostate specific antigen (1)
• prostatectomy (4)
• prostate-specific antigen (3)
• ProtecT (1)
• PROTECT trial (1)
• PRO-TECT trial (1)
• proton beam radiotherapy (2)
• proton therapy (3)
• provider roles (1)
• prudence francis (2)
• PSA (5)
• psychiatry and cancer (1)
• psychological (1)
• psychological experience (1)
• psychological intervention (1)
• psychological support (1)
• psycho-oncology (1)
• psychosocial (3)
• psychosocial care (3)
• psychosocial distress screening (1)
• psychosocial services (1)
• PTCL (3)
• public health (1)
• pyramid trial (1)
• Qian Shi (1)
• QMAP (1)
• qol (5)
• QTP (1)
• QUADRA (1)
• quadruplet (1)
• quality (1)
• quality assessment (1)
• quality cancer care (2)
• quality care (20)
• quality care in cancer (1)
• quality control (1)
• quality improvement (3)
• quality in cancer care (2)
• quality measurement (1)
• quality measures (1)
• quality of care (3)
• quality of life (33)
• quality of life survivor (1)
• quality reporting (1)
• quality training (1)
• quality-adjusted survival (1)
• quazar trial (1)
• Queen Elizabeth Hospital (1)
• Queen Mary University of London (5)
• quitting smoking (1)
• Quyen Chu (2)
• R. Angelo de Claro (2)
• R. GREGORY BOCIEK (1)
• Raamis Khwaja (1)
• Rabin Medical Center (2)
• race (2)
• Rachel Freedman (1)
• Rachel Grisham (1)
• Rachel Joseph (1)
• Rachel Lynn Yung (2)
• Rachel Tompa (1)
• Rachelle Bernacki (2)
• racial disparities (2)
• racial disparity (1)
• RAD001 (1)
• Radhakrishna Vemuri, Jo Cavallo (1)
• RADIANT-4 (1)
• radiation (10)
• radiation boost (1)
• radiation dose (1)
• radiation fractionation (2)
• radiation oncology (6)
• radiation oncology service (1)
• radiation therapy (14)
• radical cystectomy (1)
• radical prostatectomy (4)
• radioactive iodine (1)
• radioembolization (1)
• radiographic pfs (1)
• radioimmunotherapy (2)
• radiology (1)
• radiosurgery (2)
• radiotherapeutic sensitivity (1)
• radiotherapy (37)
• radiotherapy deintensification (1)
• radiotherapy delivery (1)
• radiotherapy dose (1)
• radiotherapy oral complications (1)
• radiotherapy safety (1)
• radium (1)
• Radium 223 (1)
• RADPAC trial (1)
• Rafal Dziadziuszko (1)
• Rafat Abonour (2)
• RAINFALL trial (1)
• Rajiv Pruthi (1)
• Rajiv Shah (1)
• Rakesh Chopra (5)
• Ralph Hauke (2)
• Ramaswamy Govindan (4)
• Ramesh Ramanathan (1)
• RAMI MANOCHAKIAN (1)
• Ramu Kandasamy (1)
• ramucirumab (4)
• Rana McKay (7)
• Randall Holcombe (1)
• Randi Gould (3)
• Randy Sweis (1)
• Randy Wei (1)
• range trial (1)
• Ranjana Advani (1)
• RANK lignad inhibitors (1)
• Raphael E. Pollock (1)
• rare cancers (1)
• rare mutations (1)
• rare tumors (2)
• RARG coding variant (1)
• RAS (2)
• RAS wild type (1)
• Rashmi Chugh (1)
• RAS-mutation (1)
• RATIFY trial (1)
• RAVI AMARAVADI (1)
• Ravi Mehrotra (2)
• Ravindran Kanesvaran (1)
• Rawad Elias (2)
• Ray Page (1)
• rbc (1)
• RCC (25)
• R-CHOP (7)
• R-CHP (1)
• REBECCA GLOMMEN (1)
• Rebecca Johnson (2)
• Rebecca Karp Leaf (1)
• Rebecca Roy Thomas (1)
• Rebecca Saracino (1)
• RECORD 1 Trial (1)
• record encounters (1)
• rectal cancer (8)
• rectal toxicity (1)
• recurrence (6)
• recurrence score (1)
• recurrent cancer (2)
• recurrent disease (1)
• recurrent glioma (1)
• recurrent head and neck cancer (1)
• recurrent ovarian cancer (2)
• red blood cell transfusion (2)
• reduced high-dose volume radioth (1)
• reduced intensity (2)
• reducing opioid use (1)
• reducing opioids (1)
• reduse trial (1)
• Reena A. George (1)
• reflect study (1)
• refractory (15)
• refractory disease (6)
• refractory Hodgkin lymphoma (1)
• refractory mm (1)
• refractory multiple myeloma (2)
• Regine Nshimiyimana Maniraho (2)
• regression-free survival (1)
• rehabilitation (1)
• reimbursement (2)
• relapsed (12)
• relapsed cancer (2)
• relapsed disease (4)
• relapsed mm (1)
• relapsed multiple myeloma (2)
• relapsed PTCL (1)
• relapsed/refractory (2)
• relapsed/refractory disease (2)
• relaxation (1)
• relay trial (1)
• RELEVANCE trial (1)
• remission (3)
• Rena Conti (1)
• renal cancer (4)
• renal cell (1)
• renal cell carcinoma (51)
• Renata Urban (1)
• RENEE MARIA SALIBY (1)
• research (1)
• research infrastructure (1)
• resectable (2)
• resectable cancer (2)
• resectable gastric cancer (1)
• resectable pancreatic cancer (1)
• resected disease (1)
• resected non small cell lung can (1)
• resection (5)
• Reshma Jagsi (2)
• residual disease (2)
• residual distant recurrence (1)
• residual invasive disease (1)
• resilience (2)
• resistance mechanisms (2)
• resistance pathways (1)
• RESONATE-2 trial (1)
• resource availability (1)
• resources (1)
• respiratory distress (1)
• response rate (1)
• response to treatment (1)
• response-adapted chemotherapy (1)
• restrictive prescribing (1)
• ret fusion (1)
• ret inhibitor (1)
• retrospective (1)
• Reverend Tawana Davis (1)
• rhabdoid (1)
• rhabdoid rcc (1)
• rhabdomyosarcoma (1)
• ribociclib (1)
• Rich Rubenstein (1)
• Richard A. Berjian (1)
• Richard Ablin (2)
• Richard Boxer (3)
• Richard Brodkin (1)
• Richard Cassidy (1)
• Richard Champlin (1)
• Richard E. Harris (1)
• Richard Finn (4)
• Richard Fisher (4)
• Richard G. Abramson (1)
• Richard Goldberg (3)
• Richard Grenell (1)
• Richard Herrmann (1)
• Richard Hite (1)
• Richard Hoppe (1)
• Richard J. Boxer (18)
• Richard L. Schilsky (1)
• Richard Lee (1)
• Richard Levine (1)
• Richard M. Boulay (2)
• Richard M. Stone (5)
• Richard Margolese (4)
• Richard Pazdur (9)
• Richard S. Finn (1)
• Richard Schilsky (7)
• Richard Stone (9)
• right side tumor (1)
• right to try (2)
• rigosertib (1)
• Rigshospitalet (1)
• Rimas Lukas (5)
• Rinaa Punglia (1)
• ring sideroblasts (1)
• Rishi Surana (2)
• rising costs (1)
• risk assessment (1)
• risk of death (2)
• risk score (1)
• risk status (1)
• risk stratification (3)
• rituximab (27)
• rituximab follicular lymphoma (1)
• rituximab maintenance (2)
• rituximab-refractory (1)
• rivaroxaban (1)
• roar trial (1)
• Robert A. Swarm (1)
• Robert Bonney (1)
• Robert Carlson (6)
• Robert Chapman (1)
• Robert Coleman (2)
• Robert Croyle (2)
• Robert Figlin (2)
• Robert H. Lurie (3)
• Robert Haddad (1)
• Robert Harrison (1)
• Robert J. Green (1)
• Robert J. Jones (1)
• Robert Kuske (2)
• Robert L. Coleman (2)
• Robert Livingston (1)
• Robert Manges (1)
• Robert Marcus (1)
• Robert Miller (3)
• Robert Motzer (2)
• Robert Peter Gale (19)
• Robert Rifkin (2)
• Roberto Leon-Ferre (1)
• Roberto Luksch (1)
• Robin Hardbattle (1)
• Robin Zon (1)
• robot-assisted surgery (1)
• robotic (1)
• rocapuldencel-T (1)
• Roger G. Lawrence (1)
• Roger Henriksson (1)
• Roger Rawlings (1)
• Rogerio Lilenbaum (1)
• Roisin Connolly (1)
• Roland Seiler (2)
• rolapitant (1)
• role function (1)
• Rolf Stahel (2)
• Romain Cohen (1)
• Romana (2)
• Romano 1 (1)
• Romano 2 (1)
• romidepsin (1)
• Ronald A. DePinho (8)
• Ronald Blum (1)
• Ronald Buckanovich (2)
• Ronald Chen (3)
• Ronald DePinho (1)
• Ronald E. Turk (1)
• Ronald Go (2)
• Ronald Hoffman (1)
• Ronald Maggiore (1)
• Ronald Piana (880)
• Ronit Leiba (1)
• Rosa Nouvini (1)
• Roswell Park (2)
• rovalpituzumab tesirine (1)
• Rova-T (3)
• Rowan Chlebowski (4)
• Roy Decker (2)
• Roy Herbst (7)
• Roy S. Herbst (1)
• Royal Brompton Hospital (1)
• Royal Marsden (1)
• Royal Marsden Hospital (5)
• Royal Marsden Hospital NHS Trust (1)
• Royal Marsden NHS Foundation Tru (1)
• Royal Marsden NHS Foundation Trust (1)
• Rozalina G McCoy (1)
• rpfs (1)
• rt (1)
• RTOG (3)
• RTOG 0415 (4)
• RTOG 0539 (1)
• RTOG 0617 (2)
• RTOG 9601 (3)
• RTOG trial (1)
• RTOG0521 (1)
• Ruben A. Mesa (1)
• Ruben Mesa (11)
• rucaparib (2)
• Rudiger Hehlmann (1)
• Rujuta Saksena (2)
• rural cancer care (1)
• rural health care (2)
• Rush Medical College (2)
• Rush University Medical Center (3)
• Rustam Tursun-Zade (1)
• Rutgers Cancer Institute (2)
• Rutgers University (1)
• Ruth Etzioni (1)
• Ruth Mary Parks (1)
• Ruth O’Regan (1)
• Ruth O'Regan (8)
• ruxolitinib (1)
• Rwanda (1)
• Ryan Nguyen (1)
• Ryan Rodriguez (1)
• S. MONICA SONI (4)
• S. Vincent Rajkumar (11)
• s-1 (3)
• Saad Usmani (6)
• Saad Z. Usmani (1)
• SABCS (2)
• SABCS 2015 (31)
• SABCS 205 (1)
• Saber Boutayeb (1)
• Sabin Russell (1)
• Sabine Linn (1)
• Sabine Siesling (2)
• sabr (2)
• SABR-COMET (2)
• sacituzumab govitecan (2)
• Safa El Kefi (1)
• safe opiod disposal (1)
• safe opiod storage (1)
• safety (1)
• safety in cancer care (1)
• safety incidents (1)
• Sagar Lonial (24)
• SAID AFQIR (1)
• Saitama Medical University International Medical Center (1)
• Salah Osman (1)
• Salah-Eddin Al-Batran (3)
• salivary gland (1)
• salivary glands (1)
• Sally Luckett (1)
• salvage management (1)
• salvage radiation (1)
• salvage radiation therapy (2)
• salvage radiotherapy (2)
• salvage therapy (1)
• salvage treatment (1)
• Sam Silver (3)
• Sameer Mahesh (1)
• Samer Khaled (1)
• Samlau Kutana (1)
• Samuel A. Kareff (1)
• Samuel Chao (2)
• Samuel Oschin Comprehensive Canc (1)
• Samuel Rosner (1)
• Samuel Rubinstein (1)
• Samuel Silver (3)
• Samuel Smith (1)
• Samuel Stevens (1)
• San Antonio Breast (54)
• San Antonio Breast Cancer Sympos (67)
• san antonio breast cancer symposium (1)
• San Antonio Cancer Center (1)
• San Camillo Forlanini Hospital (2)
• San Raffaele Hospital (2)
• Sandeep S. Arora (1)
• Sandip Patel (1)
• SANDPIPER (1)
• Sandra Swain (1)
• Sandra Wong (1)
• Sandro Pignata (1)
• Sandton Oncology Centre (1)
• Sanjeev Arora (1)
• SANTOSH RAO (1)
• Santosshi Narayanan (1)
• Saoussane Kharmoum (1)
• Sapna Pradyuman Patel (1)
• sar650984 (1)
• Sara Christensen (1)
• Sara Gafni (1)
• Sara Hurvitz (3)
• Sara Tolaney (2)
• Sarah Bachmann (1)
• Sarah Blair (1)
• Sarah Brand (1)
• Sarah Cannon Research Institute (2)
• Sarah Goldberg (1)
• Sarah Hoffe (1)
• Sarah Holstein (3)
• Sarah Hopkins (2)
• Sarah Jackson (25)
• Sarah Prinsloo (1)
• Sarah Sammons (1)
• Sarah Stream (1)
• Sarah Weiss (1)
• Sarah Yagerman (1)
• Sarat Chandarlapaty (3)
• sarcoma (2)
• Sarcoma (3)
• sarcomatoid (3)
• sarcomatoid rcc (1)
• sarcopenia (1)
• Sarfraz Ahmad (1)
• Sarina Isenberg (1)
• Saro Armenian (1)
• Satish Gopal (1)
• Sattva Neelapu (1)
• savolitinib (1)
• SBRT (13)
• scalp cooling (1)
• SCALP trial (1)
• SCLC (9)
• score theory (1)
• SCOT trial (1)
• Scott Hamilton (1)
• Scott Irwin (1)
• Scott Kopetz (1)
• SCOTT LITOW (1)
• Scott Wilson (1)
• screening (1)
• screening eligibility (1)
• Scripps Health (1)
• Sean Smith (2)
• Seattle Cancer Care Alliance (2)
• Seattle Children’s Hospital (1)
• Seattle Children's Hospital (1)
• Sebastien Maury (2)
• Sébastien Maury (1)
• second cancer (1)
• second cancers (1)
• second opinions (1)
• secondary cancers (1)
• second-line therapy (4)
• second-line treatment (3)
• Sedan Dulgarian (1)
• sedation (1)
• Seema A. Khan (1)
• Seema Bhat (2)
• Seema Khan (2)
• SEER database (2)
• Sehn (1)
• Seidman Cancer Center (1)
• selecting treatment (1)
• self-management (1)
• Selina M. Luger (1)
• Selma Schimmel (1)
• semaphorin 4d (1)
• seminoma (1)
• sentinel nodes (1)
• Seoul National U. Cancer Hospita (1)
• Seoul National University Hospit (1)
• Seppo Langer (1)
• sequenced therapies (1)
• sequencing agents (1)
• sequencing therapy (4)
• Sergey Kozhukhov (1)
• Sergio Giralt (1)
• serial (1)
• serial care (1)
• serious illness care (1)
• serious ovarian cancer (1)
• serous ovarian cancer (1)
• serum cytokines (1)
• serum-based biomarker (1)
• Setting Tags (1)
• sexual aids (1)
• sexual function (2)
• sexual gender minorities (1)
• Shahrukh Hashmi (1)
• Shailender Bhatia (2)
• Shaji Kumar (5)
• Shaker Dakhil (1)
• Shakira Grant (3)
• Shalmali Pal (13)
• Shannon Coleman (1)
• Shannon MacDonald (1)
• Shannon Ugarte (2)
• Shanta Boles (1)
• Shanu Modi (2)
• shared decision making (1)
• Sharon Barger (1)
• Sharon Berenfeld (1)
• Sharon Donovan (1)
• Sharyn Kurtz (1)
• Shawn Amer (1)
• Shawn Farrah (1)
• Shawna Hudson (1)
• Sheila Garland (1)
• Sheila Leatherwood (1)
• Sheila McGlown (1)
• Sheila N. Garland (1)
• Sheila Ross (1)
• Shekinah Nefreteri Elmore (1)
• Shelly Latte-Naor (5)
• Sherene Loi (3)
• Sheri Sobrato Brisson (1)
• Sherri Rosenthal (1)
• Shiao-Pei Weathers (1)
• Shiliang Zhang (1)
• Shilo Kramer (1)
• Shira Klapper (1)
• Shirlee Simpson (1)
• Shirley Grandahl (1)
• Shoshana Rosenberg (1)
• Shou-Ching Tang (1)
• Shradda Dalwadi (1)
• Shreya Desai (1)
• Shridar Genevan (1)
• Shrinivas Rathod (1)
• Shulian Wang (1)
• Shumei Song (1)
• Sian Pugh (1)
• siblings (1)
• Sibylle Loibl (3)
• side effects (4)
• Sideny Kimmel Cancer Center (1)
• Sidney Kimmel Cancer Center (1)
• Sidney Kimmel Comprehensive Canc (2)
• Sidney Kimmel Comprehensive Cancer Center (1)
• Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University (1)
• Sigrid Barklund (1)
• Silvia Novello (2)
• Silvio Monfardini (9)
• Simon Cancer Center (1)
• Simon Davies (1)
• Simon Rule (2)
• Simone Consulting Company (2)
• Simone Koole (1)
• Simron Singh (2)
• Sincere McMillan (1)
• Sindhuja Kadambi (1)
• single fraction (1)
• single-agent therapy (1)
• single-dose radiotherapy (1)
• single-gene test (1)
• Sir Murray F. Brennan (2)
• sirolimus (1)
• SITC (22)
• Siteman Cancer Center (1)
• skeletal event (1)
• skin cancer (25)
• Skin Cancer (9)
• skin toxicities (1)
• sleep disturbances (1)
• SLL (6)
• SLNB-positive (1)
• small cell lung cancer (10)
• small lymphocytic leukemia (2)
• small lymphocytic lymphoma (2)
• small molecule inhibitors (1)
• small-molecule inhibitor (1)
• smart start (1)
• smartphone app (1)
• Smilow (1)
• Smilow Cancer Hospital (3)
• Smita Banerjee (1)
• Smita Bhatia (4)
• Smith Breast Center (1)
• Smith Giri (1)
• smoking (3)
• smoking cessation (2)
• smoldering myeloma (5)
• So Yeon Kim (1)
• social function (1)
• soft tissue sarcoma (1)
• SOFT trial (8)
• soft-tissue sarcoma (2)
• Sola Kim (1)
• Solange Peters (2)
• SOLAR trial (1)
• SOLAR-1 (1)
• solid cancers (1)
• solid tumors (8)
• Solid Tumors (4)
• SOLO2 trial (2)
• solo3 (1)
• somatic mutation (1)
• Somnath Mukherjee (2)
• Sonali Smith (6)
• Sonia Ray (1)
• Sonja Vliek (1)
• Sonja Zweegman (1)
• Sophia Kustas Smith (1)
• sophia trial (2)
• sorafenib (10)
• soritinib (1)
• Sormain trial (1)
• sotatercept (1)
• South Texas Oncology and Hematology (1)
• Southampton University Hospital (1)
• Southwest Oncology Group (1)
• spanish-speaking (1)
• SPARTAN trial (1)
• SPCG-13 trial (1)
• sperm bank (1)
• spinal cord compression (1)
• spinal instability (1)
• spinal lesions (1)
• spinal metastases (1)
• spleen (1)
• splenectomy (1)
• splenic volume (1)
• splicing modulator (1)
• sporadic breast cancer (1)
• SPPORT trial (1)
• squamous (2)
• squamous carcinoma (1)
• squamous cell (2)
• squamous cell carcinoma (6)
• squamous lung cancer (1)
• squamous NCLC (2)
• SQUIRE (1)
• SQUIRE trial (2)
• Srdan Verstovsek (1)
• Srikala Sridhar (2)
• Srinadh Komanduri (1)
• Sriram Yennu (1)
• St. Jude (2)
• St. Jude Children's (1)
• St. Jude Children's Research Hos (1)
• St. Jude Family Advisory Council’s Subcommittee on Quality of Life and Palliative Care (1)
• Stacey Berg (1)
• Stacyann Bailey (1)
• stage 4 (1)
• stage data (1)
• stage I (1)
• stage I cancer (1)
• stage I testicular cancer (1)
• stage II (2)
• stage II breast cancer (1)
• stage III (1)
• stage III breast cancer (1)
• stage III cancer (1)
• Stage III disease (1)
• stage III melanoma (1)
• stage IV disease (1)
• stage IV lung cancer (2)
• staging (1)
• staging criteria (1)
• staging quality (1)
• STAMPEDE (1)
• STAMPEDE trial (10)
• Stan Winokur (2)
• standard of care (2)
• standard radiotherapy (1)
• standard therapy (1)
• Stanford (1)
• Stanford Cancer Center (1)
• Stanford Cancer Institute (5)
• Stanford Health Care (1)
• Stanford School of Medicine (1)
• Stanford University (8)
• Stanford University Medical Center (1)
• Stanford University School of Me (1)
• Stanley M. Marks (1)
• STAR trial (1)
• starting mammography age (1)
• state of cancer care (3)
• state of the art (1)
• statins (1)
• statistical analysis (1)
• Stay With Me Awhile (1)
• Stefan Ciurea (1)
• Stefan Terwindt (1)
• Stefano Signoroni (1)
• stem cell transplant (2)
• steml cell transplant (1)
• step-care approach (1)
• Stephan Stilgenbauer (4)
• Stephanie Graff (2)
• Stephanie Walker (1)
• Stephen Ansell (5)
• Stephen Chandler (1)
• Stephen Chun (2)
• Stephen Forman (2)
• Stephen Fox (1)
• Stephen Gottschalk (1)
• Stephen Johnston (1)
• Stephen R.D. Johnston (1)
• Stephen Sagar (1)
• Stephen Schuster (2)
• Stephen Sonis (1)
• step-wise guidance (1)
• stereotactic (1)
• stereotactic ablative radiation (3)
• stereotactic body radiation ther (2)
• stereotactic body radiotherapy (8)
• stereotactic radiation (1)
• Steven E. Vogl (6)
• Steven Horwitz (4)
• Steven Kalister (1)
• Steven Le Gouill (2)
• Steven Narod (1)
• Steven Nurkin (1)
• Steven Shak (1)
• Steven Treon (1)
• Steven Vogl (13)
• stigma (1)
• StiL trial (1)
• STREAM (1)
• strength training (1)
• stress (2)
• stress management (2)
• stroma (1)
• stromal tumor (1)
• stromal tumor-infiltrating lymph (1)
• structured reporting (1)
• Stuart Lichtman (3)
• Stuart M. Lichtman (12)
• Subeera Khan (1)
• subserosal (1)
• substance use disorders (1)
• subtypes (1)
• SUCCESS A trial (1)
• Sudhir Srivastava (2)
• Sue Yom (1)
• suffering (1)
• suicide (3)
• suicide ideation (1)
• suicide risk (1)
• Suleika Jaouad (1)
• Sumanta Kumar Pal (1)
• Sumanta Pal (11)
• Sumit Agarwal (1)
• Sumit Shah (1)
• Suneel Kamath (1)
• sunitinib (22)
• sunitinib vaccine (1)
• Sunnybrook Health Sciences Centr (1)
• Sunnybrook Odette Cancer Centre (1)
• support services (1)
• supportive care (8)
• Supportive Care (3)
• Supriya Chopra (2)
• Supriya Mohile (1)
• Suresh Ramalingam (4)
• Suresh S. Ramalingam (2)
• surgery (6)
• surgery volumes (1)
• surgical cytoreduction (1)
• surgical management (1)
• surgical oncology (9)
• surgical resection (1)
• surgical site infection (1)
• surgically resectable (1)
• surgically resected patients (1)
• surprise conversation (1)
• surrogate endpoint (1)
• survaxm (1)
• surveillance testing (1)
• survey (1)
• surviellance therapy (1)
• survival (7)
• survival analysis (2)
• survival in cancer (1)
• survival rates (1)
• survival registry (1)
• survivin (1)
• survivor (2)
• survivorship (24)
• Survivorship (3)
• survivorship care (2)
• survivorship provider (1)
• survivorship standard (1)
• survivorship-specific programs (1)
• Susan Cohn (1)
• Susan Falbo (1)
• Susan Faye Dent (1)
• Susan London (79)
• Susan M. O’Brien (1)
• Susan O’Brien (1)
• Susan O'Brien (3)
• Susan Reckling (23)
• Susan Slovin (1)
• Susan Swanson (1)
• Susana Banerjee (1)
• susceptibility (1)
• Sushil Bhardwaj (1)
• sustainable efforts (1)
• Suzanna Zick (1)
• Suzanne George (1)
• Suzi Tortora (1)
• Swedish Cancer Institute (1)
• switch maintenance (1)
• SWOG (3)
• SWOG 0819 (1)
• SWOG 1406 (1)
• SWOG S0819 (1)
• SWOG S0927 (1)
• SWOG S1117 (1)
• SWOG S9921 (1)
• SWOG-8814 (1)
• SWOGS0307 (1)
• Syed (1)
• Syed A. Abutalib (7)
• Syed Abutalib (55)
• Syed Ali Abutalib (68)
• SYK/JAK (1)
• Sylvester Comprehensive Cancer Center at the University of Miami (3)
• Sylvie Leotin (1)
• symptom assessment (1)
• symptom burden (1)
• symptom control (3)
• symptom management (7)
• Symptom Management (2)
• symptom monitoring (1)
• symptom reduction (1)
• symptomatic relapse (2)
• systemic chemotherapy (1)
• systemic disease (1)
• systemic therapy (5)
• systemic treatment (1)
• systems of care (1)
• T cell (2)
• T cells (5)
• T. Ming Chu (1)
• T1 tumors (1)
• T1-2N0M0 (1)
• T3 resectable cancer (1)
• T790M mutation (1)
• tags trial (1)
• tailored therapy (1)
• TAILORx (6)
• Takeshi Kodaira (1)
• Talal Hilal (1)
• Talapro-2 (1)
• talazoparib (1)
• Talha Shaikh (1)
• Tamim Niazi (1)
• Tammie Denyse (1)
• Tammy Schuler (2)
• tamoxifen (16)
• tamoxifen adherence (1)
• Tamy Kim (2)
• Tanya Dorff (1)
• Tanya M. Wildes (1)
• Tanya Spektor (1)
• Tanya Wildes (1)
• Taofeek Owonikoko (1)
• tappas trial (1)
• TAPUR (1)
• Tara Henderson (2)
• targeted agents (2)
• targeted biologics (1)
• targeted therapy (6)
• targeted treatment (9)
• targeted treatments (7)
• taselisib (1)
• Tata Memorial Centre (1)
• Tata Memorial Hospital (2)
• Tatiana Prowell (2)
• Taussig Cancer Institute (1)
• taxane (3)
• taxol (1)
• Taylor Bell Duck (1)
• TBCRC 024 (1)
• t-cell checkpoint (1)
• T-cell therapy (1)
• T-DM1 (5)
• t-dxd (1)
• TEAM IIb trial (1)
• team management (1)
• tecemotide (1)
• technology (1)
• tegafur (1)
• telehealth (2)
• telemedicine (1)
• Temidayo Fadelu (1)
• temozolomide (1)
• temsirolimus (2)
• Teresa Calimeri (2)
• Teresa Pedersen (1)
• terminal cancer (1)
• Terri Coutee (1)
• Terry Fry (1)
• test (1)
• testicular cancer (6)
• testosterone suppression (1)
• Texas A&M (1)
• Texas Children's Hospital (1)
• TEXT trial (2)
• tgr-1202 (1)
• TH3RESA trial (1)
• Thaddeus Mason Pope (17)
• The Angeles Clinic and Research (1)
• The ASCO (1)
• The ASCO Post (4155)
• The ASCO Post Staff (5125)
• The Christie NHS Foundation Trust (1)
• the editors (1)
• the mednet (1)
• The Netherlands Cancer Institute (1)
• The Ohio State University (5)
• The Royal Marsden (2)
• The Royal Marsden NHS Foundation (1)
• The Royal Marsden NHS Foundation Trust (3)
• The University of Chicago (1)
• The University of Colorado (1)
• The University of Manchester (2)
• The University of Sydney (1)
• The University of Texas MD Anderson Cancer Center (21)
• The University of Texas Southwestern Medical Center (1)
• The West Clinic (1)
• Theodora Karnakis (1)
• Theodore Lawrence (1)
• Theodore Yaeger (1)
• therapeutic response (1)
• Therese Bevers (3)
• Thierry Andre (1)
• third generation inhibitors (1)
• Thomas Abrams (1)
• Thomas Buchholz (2)
• Thomas D'Amico (2)
• Thomas E. Witzig (1)
• Thomas Goode (1)
• Thomas J. Lynch Jr (1)
• Thomas J. Roberts (1)
• Thomas J. Smith (1)
• Thomas Jefferson University Hosp (2)
• Thomas LeBlanc (2)
• Thomas Lester (1)
• Thomas Powles (2)
• Thomas Smith (1)
• Thomas Stinchcombe (1)
• thoracic cancer (2)
• Thoracic Cancers Symposium (23)
• thoracic malignancies (1)
• thoracic radiation (1)
• thoracic radiotherapy (1)
• thoracic vertebral bodies (1)
• thoracolaparoscopic (1)
• thoracoscopic lobectomy (1)
• thromboctyopenia (1)
• thrombocythaemia (1)
• thrombocytopenia (1)
• thromboprophylaxis (2)
• thrombosis (1)
• thrombotic thrombocytopenic purp (1)
• thymic epithelial tumors (1)
• thyroid cancer (4)
• Thyroid Cancer (1)
• thyroid palpation (1)
• Tia Higano (4)
• Tiffany Fagnani (1)
• Tiffany H. Williams (1)
• TIGERx study (1)
• TILs (3)
• Tim Ahles (2)
• TIM BARTHOLOW (1)
• Tim Donald (2)
• timely treatment (1)
• Timothy Fenske (1)
• Timothy Gilligan (2)
• Timothy Murtha (1)
• Timothy Quill (1)
• Timothy S. Fenske (1)
• Timothy Wilt (1)
• Tina Marin (1)
• Ting Bao (18)
• tipiracil (1)
• Tisch Cancer Institute (1)
• titan trial (2)
• tivo-3 trial (1)
• tivozanib (1)
• TK1 (1)
• TK1 resistance (1)
• TKI (7)
• TKI resistance (1)
• tkis (1)
• tmb (1)
• TNBC (13)
• TNM staging (1)
• TNT trial (2)
• tobacco cessation (1)
• Toby Campbell (1)
• Todd Gibson (1)
• Todd Palmby (1)
• Todd Pickard (1)
• Tom Baker Cancer Centre (1)
• Tom Whitehead (1)
• Tomma Hargraves (1)
• Tommy Donbavand (1)
• Toni Choueiri (16)
• TONIC trial (1)
• Tonie Forster (1)
• Tony K.W. Hung (1)
• Tony Mok (14)
• Torben Plesner (2)
• Tori Brunetti (1)
• Toronto Sunnybrook Cancer Centre (1)
• Toshihiko Doi (2)
• total cancer care (1)
• total neoadjuvant therapy (1)
• toxicities (2)
• toxicity (18)
• toxicity burden (1)
• Tracey Aiello (1)
• Tracey Danaher (1)
• Tracey Evans (1)
• Tracy Balboni (1)
• Tracy Batchelor (3)
• trametinib (5)
• transcend cll 004 (1)
• TRANSCEND NHL 001 (1)
• transitional cell carcinoma (1)
• translational research (1)
• transperineal radiation (1)
• trastuzumab (18)
• trastuzumab deruxtecan (2)
• trastuzumab emtansine (4)
• trastuzumab emtasine (1)
• trastuzumab-resistant disease (1)
• trasutuzmab (1)
• Traver Hutchins (1)
• trc105 (1)
• treatment adherence (3)
• treatment advances (1)
• treatment burden (3)
• treatment completion (1)
• treatment deferment (1)
• treatment deintensification (3)
• treatment delays (1)
• treatment disparities (1)
• treatment duration (2)
• treatment efficacy (1)
• treatment errors (1)
• treatment guidelines (1)
• treatment intensification (1)
• treatment modality (1)
• treatment outcomes (2)
• treatment paradigms (1)
• treatment period (1)
• treatment plan (1)
• treatment plans (1)
• treatment resistance (2)
• treatment resistant (1)
• treatment response (4)
• treatment targets (1)
• treatment toxicity (1)
• treatment update (2)
• treatment volume (2)
• treatment-free remission (1)
• treatment-naive (1)
• treatment-naïve (4)
• treatment-refractory (1)
• tree nuts (1)
• tremelimumab (1)
• Trent Tipple (1)
• trial enrollment (2)
• trifluridine (1)
• trigger (1)
• trimodality therapy (1)
• triple negative breast cancer (2)
• triple-negative breast cancer (30)
• triplet (1)
• triplet regimen (1)
• Tristana Vásquez (1)
• TRK fusion (1)
• tropomyosin receptor kinase inhi (1)
• TRUS biopsy (1)
• tucatinib (1)
• Tulane (2)
• Tulane Cancer Center (1)
• Tulane University (1)
• tumor biology (1)
• tumor boards (1)
• tumor complexity (1)
• tumor gene expression (1)
• tumor infiltrating lymphocyte (1)
• tumor location (1)
• tumor microenvironment (2)
• tumor mutational burden (2)
• tumor profiling (4)
• tumor proportion score (3)
• tumor response (1)
• tumor sidedness (2)
• tumor treating fields (1)
• tumor-infiltrating lymphocytes (2)
• tumors (1)
• Tuya Pal (1)
• Ty Higuchi (1)
• Tycel Phillips (1)
• Tyler Stewart (1)
• tyrosine kinase inhibitor (11)
• U Alabama at Birmingham (1)
• U Alabama Cancer Center (1)
• U Colorado Cancer Center (1)
• U Colorado Health Science Center (1)
• U Michigan Cancer Center (1)
• UAB Comprehensive Cancer Center (1)
• ublituximab (2)
• UC Davis (1)
• UC Irvine (2)
• UC San Diego (4)
• UC San Diego Moores (1)
• UC San Francisco (6)
• UCLA (12)
• UCLA David Geffen School of Medicine (2)
• UCLA Fielding School of Public Health (1)
• UCLA Jonsson (3)
• UCLA Medical Center (3)
• UCSD (2)
• UCSF (5)
• UCSF Helen Diller (1)
• Ugo Pastorino (2)
• Ujwal Yanala (1)
• ulcerative colitis (1)
• ultra-high risk relapsed/refract (1)
• ultrasensitive detection (1)
• Umberto Vitolo (1)
• Umbraco (1)
• umbrella study (1)
• Umea University Hospital (1)
• UNC (3)
• UNC Chapel Hill (4)
• UNC health care (1)
• UNC School of Medicine (1)
• underserved (1)
• underserved cancer patients (1)
• underserved populations (1)
• undertreatment (1)
• unequal survival (1)
• unilateral (1)
• unilateral breast cancer (1)
• Union for International Cancer Control (1)
• UnitedHealth Group (1)
• UnitedHealthCare (2)
• Universitaetsklinikum des Saarla (1)
• University Clinic of Navarra (3)
• University College London (2)
• University Hospital Basel (1)
• University Hospital Erlangen (1)
• University Hospital Essen (2)
• University Hospital Heidelberg (1)
• University Hospital Hôtel-Dieu (1)
• University Hospital Leuven (1)
• University Hospital of Lille (2)
• University Hospital Zurich (1)
• University Hospitals Gasthuisber (1)
• University Hospitals Leuven (3)
• University Medical Center Gronin (1)
• University of Alabama at Birming (2)
• University of Alabama Birmingham (4)
• University of Alberta (1)
• University of Amsterdam (1)
• University of Arizona (1)
• University of Athens (1)
• University of Barcelona (2)
• University of Basel (1)
• University of British Columbia (5)
• University of Calgary (1)
• University of California (2)
• University of California Irvine (1)
• University of California San Die (2)
• University of California San Francisco (3)
• University of Cambridge (1)
• University of Chicago (11)
• University of Colorado (3)
• University of Colorado at Denver (1)
• University of Colorado Cancer Ce (1)
• University of Edinburgh (1)
• University of Florida (1)
• University of Gothenburg (1)
• University of Greifswald (2)
• University of Illinois Chicago (1)
• University of Iowa Carver College of Medicine (1)
• University of Iowa Hospital (1)
• University of Kentucky (1)
• University of Lausanne (2)
• University of Leeds (2)
• University of Liverpool (1)
• University of Manitoba (1)
• University of Maryland (1)
• University of Maryland Medical C (1)
• University of Maryland Medical Center (1)
• University of Memphis (1)
• University of Miami Health Syste (1)
• University of Michigan (8)
• University of Michigan Health Sy (2)
• University of Milan (1)
• University of Minnesota (3)
• University of Montreal (2)
• University of Nantes (1)
• University of Nebraska (7)
• University of Nebraska Medical (5)
• University of Nebraska Medical C (7)
• University of Nebraska Medical Center (3)
• University of New Mexico (2)
• University of New South Wales (1)
• University of North Carolina (16)
• University of North Carolina Lineberger Comprehensive Cancer Center (1)
• University of Paris Sud (1)
• University of Pennsylvania (12)
• University of Pittsburgh (2)
• University of Queensland (1)
• University of Rochester (1)
• University of Rochester Medical Center (1)
• University of San Diego (1)
• University of South Carolina (1)
• University of Southampton (3)
• University of Southern Californi (1)
• University of Sydney (3)
• University of Texas (1)
• University of Texas MD Anderson (1)
• University of Torino (4)
• University of Toronto (1)
• University of Tubingen (2)
• University of Tuebingen (2)
• University of Turin (1)
• University of Ulm (1)
• University of Warwick (1)
• University of Washington (10)
• University of Washington Seattle (1)
• University of Wisconsin (6)
• University of Wisconsin Carbone (2)
• University Paris Descartes (1)
• University Paris-Sud (1)
• UNMC (3)
• unrelated HCT (1)
• unresectable (2)
• unresectable bladder cancer (1)
• unresectable disease (1)
• untreated RCC (1)
• upfront surgery (1)
• upfront therapy (1)
• upfront treatment (1)
• UPMC Hillman Cancer Center (1)
• upper gastrointestinal cancer (1)
• upstaging (1)
• Uqba Khan (1)
• uracil (1)
• urban setting (1)
• urethral cancer (1)
• urinary tract cancer (1)
• urogenital cancers (1)
• urologic surgery (1)
• Uroosa Ibrahim (1)
• urothelial (1)
• urothelial cancer (12)
• urothelial carcinoma (11)
• Ursula A. Matulonis (3)
• Ursula Matulonis (3)
• Ursula Sansom-Daly (2)
• US Food and Drug Administration (2)
• US Intergroup (1)
• US Preventive Services Task Forc (1)
• USC (3)
• USC Norris (4)
• USC Norris Cancer Center (4)
• USC Norris Comprehensive Cancer Center (1)
• Usha Menon (1)
• usual care (1)
• UT Health (1)
• UT Health San Antonio Cancer Center (1)
• UT Health Science Center (1)
• UT Southwestern Medical Center (2)
• uterine cancer (1)
• UTSW (1)
• UV exposure (2)
• vaccine (3)
• vacuum-assisted (1)
• vadastuximab talirine (2)
• Vadim Gushchin (1)
• Vaishali Sanchorawala (1)
• Vali Papadimitradopoulou (1)
• Vali Papadimitrakopoulou (2)
• Valisia LeKae (1)
• Vall d'Hebron University Hospita (2)
• value (2)
• value in cancer care (3)
• value in medicine (1)
• value-based care (2)
• Vamsidhar Velcheti (2)
• Vanderbilt (1)
• Vanderbilt Ingram (3)
• Vanderbilt University (5)
• Vanessa Eaton (1)
• vaping (1)
• variation in quality (1)
• Vassiliki Papadimitrakopoulou (2)
• VEGF (1)
• VEGF blockade (1)
• VEGF inhibitor (1)
• Vejle Hospital (1)
• velia/cog-3005 (1)
• Velindre Hospital (1)
• veliparib (7)
• velipatib (1)
• vemurafenib (3)
• venetoclax (8)
• venetoclax monotherapy (1)
• venous thromboembolism (4)
• Vered Stearns (3)
• VHL (1)
• Vicki Jackson (2)
• Vicki Morrison (1)
• Victor Vogel (2)
• video tool (1)
• vigil (1)
• VIJAYA RAJ BHATT (1)
• Vinay Prasad (1)
• vinblastine (2)
• Vincent DeVita (1)
• Vincent Rajkumar (1)
• vincristine (2)
• vinflunine (3)
• Vinicius Ernani (1)
• vinorelbine (2)
• viral reactivation (1)
• Virginia Anderson (2)
• Virginia Commonwealth University (1)
• Virginia Kaklamani (1)
• Vishal Bhatnagar (1)
• Visionary Leader Award (1)
• vitamin D (2)
• Vivek Agarwala (1)
• Viviane Hess (1)
• VOLKER DIEHL (1)
• vomiting (3)
• Von-Hippel Lindau (1)
• vorinostat (2)
• Vratislav Strnad (1)
• VTE (3)
• vulvar cancer (2)
• W. Marston Linehan (1)
• W. Robert Lee (3)
• Wafik El-Deiry (1)
• Waldenström’s (1)
• Waldenström’s Macroglobulinemia (1)
• Walter Curran Jr (1)
• Warren Mason (1)
• Warwick Medical School (1)
• Washington University (2)
• Washington University School of Medicine in St. Louis (1)
• watch and wait (1)
• Watson for Oncology (1)
• Wayne Kuznar (2)
• wbi (1)
• WBRT (3)
• WCLC 2015 (24)
• wealth expenditure (1)
• wearable sensors (1)
• web-based intervention (1)
• web-based tool (1)
• weight loss (4)
• weight-based doses (1)
• weight-loss intervention (1)
• Weijing Sun (1)
• Weill Cornell Medical College (2)
• well follow-up (1)
• well tolerated (1)
• Wendy Demark-Wahnefried (1)
• Wendy Harpham (2)
• Wendy Lichtenthal (3)
• Wendy Selig (1)
• Wendy Vogel (5)
• Wendy Wing-Lok Chan (1)
• West Cancer Center (3)
• West Clinic (1)
• WHI (1)
• white blood cell growth factor t (1)
• white patients (2)
• who (1)
• WHO classification (1)
• whole brain radiation (1)
• whole brain radiotherapy (1)
• whole breast radiation therapy (3)
• whole exome sequencing (2)
• whole genome profiling (1)
• whole-brain radiotherapy (1)
• whole-breast irradiation (1)
• wild type (1)
• wild-type (2)
• wild-type KRAS (1)
• William Aronson (1)
• William Breitbart (12)
• William Catalona (1)
• William Curry (3)
• William Dale (1)
• William Gradishar (7)
• William H. Redd (1)
• William H. Sharfman (1)
• William Hall (1)
• William J.M. Hrushesky (1)
• William M. Grady (1)
• william m. sikov (2)
• William McGivney (2)
• William Meyer (1)
• William N. Harwin (1)
• WILLIAM OH (1)
• William S. Shimp (3)
• William Sikov (3)
• William Tew (1)
• William Travis (2)
• William Wierda (3)
• Wilms tumor (2)
• Winship Cancer Institute (3)
• Wolfgang Wick (1)
• women (2)
• Women and Infants Hospital of Rh (1)
• women cancer survivors (1)
• women in oncology (2)
• Women Who Conquer Cancer (2)
• Women's Health Initiative (2)
• Women's Health Initiative Dietar (1)
• workflow (1)
• workforce development (1)
• workplace stress (1)
• workshop (1)
• World Health Organization (1)
• Wui-Jin Koh (2)
• WUSTL (1)
• www.reimagine.me (1)
• Wyndham H. Wilson (1)
• Wyndham Wilson (2)
• Xin Gao (1)
• Xin Zheng (1)
• Xuesong Han (1)
• Y537S mutation (1)
• Yale Cancer Center (9)
• Yale Law (17)
• Yale School of Medicine (3)
• Yale School of Nursing (1)
• Yale University (2)
• Yale University School of Medicine (1)
• YANIN CHAVARRI-GUERRA (1)
• Yen Nien (Jason) Hou (6)
• Yen Nien Hou (5)
• Yesne Alici (1)
• Ying Taur (1)
• yoga (1)
• Yoli Origel (1)
• Yonsei Cancer Center (1)
• Yoon-Koo Kang (2)
• young adult cancer (3)
• young adult cancer survivor (1)
• young adult oncology (2)
• young adults (2)
• young breast cancer (1)
• young breast cancer patients (1)
• young breast patients (1)
• young cancer patients (1)
• young patients (2)
• young patients at end of life (1)
• young women (1)
• younger patients (3)
• Yousuf Zafar (1)
• Yulia Raskina (1)
• Yung-Jue Bang (1)
• Z. Kevin Liu (1)
• Z11 study (1)
• Zaina Qureshi (3)
• Zelenetz (1)
• Zeynep Zengin (1)
• Zhongxing Liao (2)
• Zineb Benbrahim (1)
• ZINEB DAHBI (1)
• Zofia Piotrowska (1)
• zoledronic acid (1)
• ZUMA-1 (1)
• ZUMA-1 trial (1)